TOKYO, August 21, 2025 - (JCN Newswire via SeaPRwire.com) - Sharp Corporation and Sharp Energy Solutions Corporation (*1) (hereinafter referred to as “Sharp”) have signed a memorandum of understanding (MOU) regarding the cooperation through renewable energy to advance improved access to basic services in displacement-affected areas in the Republic of Kenya (hereinafter “Kenya”). This MOU is signed with Mitsui O.S.K. Lines, Ltd. (Headquarters: Minato ward, Tokyo, hereinafter referred to as “MOL”), and the International Organization for Migration (*2) (hereinafter referred to as “IOM”), in conjunction with the 9th Tokyo International Conference on African Development (*3) (TICAD 9).(From left) Tatsuro Watanabe, Responsible for Europe and Africa Region, Chairman & Managing Director of MOL (Europe Africa) Ltd;Yasufumi Sugahara, Executive Managing Officer & Co-Chief Operating Officer, Sharp Corporation;Hirozumi Gokaku, President & Representative Director, Sharp Energy Solutions Corporation;Ritsu Nacken, Chief of Mission, IOM Japan.The MOU also stipulates that the Parties will explore innovative solutions and technologies to strengthen climate resilience of vulnerable communities in Kenya.Sharp has been promoting ESG-based management, and this MOU aligns with its corporate philosophy "to contribute to the benefits and welfare of people throughout the world." Sharp will continue to address societal challenges and fulfill its commitment to social contribution by utilizing its unique products solutions and technologies.*1 Sharp Energy Solutions Corporation is a subsidiary of Sharp Corporation responsible for energy solutions. Headquarters: Yao City, Osaka Prefecture. President and Representative Director: Hirozumi Gokaku.*2 The International Organization for Migration (IOM) is a UN agency that addresses global migration issues. IOM Japan Chief of Mission : Ritsu Nacken.*3 The TICAD 9 will be held from August 20 to August 22, 2025, at Pacifico Yokohama (Yokohama City, Kanagawa Prefecture). It is organized by the Japanese government in collaboration with the United Nations, the United Nations Development Programme (UNDP), the World Bank, and the African Union Commission (AUC).Sharp Sustainability global website: https://global.sharp/corporate/eco/ Copyright 2025 JCN Newswire via SeaPRwire.com.
Palantir ការវិភាគភាគហ៊ុន និងនិន្នាការ
(SeaPRwire) - Palantir Technologies Inc. (NYSE:PLTR) ស្ថិតក្នុងការចាប់អារម្មណ៍របស់វិនិយោគិនជាច្រើន ជាពិសេសបន្ទាប់ពីតម្លៃរបស់ខ្លួនបានឡើងខ្ពស់បំផុតជាប្រវត្តិសាស្ត្រកាលពីដើមឆ្នាំនេះ។ ទោះជាយ៉ាងណាក៏ដោយ ការកែតម្រូវទីផ្សារនាពេលថ្មីៗនេះ បានបណ្ដាលឱ្យតម្លៃភាគហ៊ុនរបស់ខ្លួនធ្លាក់ចុះ ដែលជំរុញឱ្យអ្នកវិភាគពិនិត្យយ៉ាងដិតដល់នូវកម្រិតគាំទ្រ និងតស៊ូដ៏សំខាន់។ គន្លងកំណើនរបស់ Palantir ពិតជាគួរឱ្យចាប់អារម្មណ៍ ដែលជំរុញដោយវេទិកាវិភាគទិន្នន័យដ៏រឹងមាំរបស់ខ្លួន ដែលបម្រើទាំងវិស័យរដ្ឋាភិបាល និងពាណិជ្ជកម្ម។ ទោះបីជាមានការធ្លាក់ចុះនាពេលថ្មីៗនេះក៏ដោយ គ្រឹះរបស់ក្រុមហ៊ុននៅតែរឹងមាំ ជាមួយនឹងការពង្រីកមូលដ្ឋានអតិថិជន និងការផ្តល់ជូនផលិតផលប្រកបដោយនវានុវត្តន៍ជាបន្តបន្ទាប់។ អ្នកវិភាគមានការចាប់អារម្មណ៍ជាពិសេសទៅលើរបៀបដែល Palantir នឹងដំណើរការនៅកម្រិតបច្ចេកទេសជាក់លាក់។ ភាគហ៊ុននេះទើបនឹងឈានដល់កម្រិតគាំទ្រដ៏សំខាន់ប្រមាណ ២០ ដុល្លារ ដែលជាប្រវត្តិសាស្ត្របានដើរតួជាកម្រិតទាបបំផុត។ ប្រសិនបើ Palantir បរាជ័យក្នុងការរក្សាកម្រិតនេះ វាអាចបង្ហាញពីការធ្លាក់ចុះបន្ថែមទៀត។ ផ្ទុយទៅវិញ ការស្ទុះងើបឡើងវិញពីការគាំទ្រនេះ អាចត្រួសត្រាយផ្លូវសម្រាប់ការកើនឡើងវិញ។ កត្តាសំខាន់មួយដែលជះឥទ្ធិពលដល់ចលនាតម្លៃភាគហ៊ុនរបស់ Palantir គឺអារម្មណ៍ទីផ្សារទូទៅចំពោះភាគហ៊ុនបច្ចេកវិទ្យា។ ជាមួយនឹងការកើនឡើងអត្រាការប្រាក់ និងការព្រួយបារម្ភអំពីអតិផរណា វិនិយោគិនមានការប្រុងប្រយ័ត្ន ដែលនាំឱ្យមានការលក់ចេញនៅក្នុងវិស័យបច្ចេកវិទ្យា។ ទោះជាយ៉ាងណាក៏ដោយ ទីតាំងតែមួយគត់របស់ Palantir នៅក្នុងទីផ្សារ អាចផ្តល់នូវភាពធន់ខ្លះប្រឆាំងនឹងសម្ពាធម៉ាក្រូសេដ្ឋកិច្ចទាំងនេះ។ វិនិយោគិនក៏គួរពិចារណាលើរបាយការណ៍ប្រាក់ចំណូលរបស់ Palantir ផងដែរ ដែលតែងតែបង្ហាញពីកំណើនចំណូលដ៏រឹងមាំ។ ការផ្តោតរបស់ក្រុមហ៊ុនលើការពង្រីកកិច្ចសន្យារដ្ឋាភិបាល និងការចូលទៅក្នុងឧស្សាហកម្មថ្មីៗ អាចផ្តល់នូវឱកាសកំណើនយ៉ាងច្រើន។ លើសពីនេះ ភាពជាដៃគូយុទ្ធសាស្ត្រ និងការទិញយករបស់ Palantir ទំនងជានឹងពង្រឹងសមត្ថភាពបច្ចេកវិទ្យា និងការគ្របដណ្តប់ទីផ្សាររបស់ខ្លួន។ សរុបមក ខណៈដែល Palantir Technologies Inc. ប្រឈមមុខនឹងបញ្ហាប្រឈមរយៈពេលខ្លី ទស្សនវិស័យរយៈពេលវែងរបស់ខ្លួនហាក់ដូចជាមានសង្ឃឹម។ វិនិយោគិនគួរតាមដានកម្រិតតម្លៃសំខាន់ៗ និងនិន្នាការទីផ្សារដើម្បីធ្វើការសម្រេចចិត្តប្រកបដោយការយល់ដឹង។ នៅពេលដែលក្រុមហ៊ុនបន្តច្នៃប្រឌិត និងពង្រីកខ្លួន វាមានសក្តានុពលក្នុងការទទួលបានសន្ទុះឡើងវិញ និងផ្តល់តម្លៃដល់ម្ចាស់ភាគហ៊ុន។ Footnotes: អត្ថបទនេះត្រូវបានផ្តល់ជូនដោយអ្នកផ្គត់ផ្គង់មាតិកាដែលទីបញ្ចូល។ SeaPRwire (https://www.seaprwire.com/) មិនមានការធានា ឬ បញ្ចេញកំណត់ណាមួយ។ ប្រភេទ: ព័ត៌មានប្រចាំថ្ងៃ, ព័ត៌មានសំខាន់ SeaPRwire ផ្តល់សេវាកម្មផ្សាយពាណិជ្ជកម្មសារព័ត៌មានសកលសម្រាប់ក្រុមហ៊ុន និងស្ថាប័ន ដែលមានការចូលដំណើរការនៅលើបណ្ដាញមេឌៀជាង 6,500 បណ្ដាញ ប័ណ្ណប្រតិភូ 86,000 និងអ្នកសារព័ត៌មានជាង 350 លាន។ SeaPRwire គាំទ្រការផ្សាយពាណិជ្ជកម្មជាសារព័ត៌មានជាភាសាអង់គ្លេស ជប៉ុន ហ្រ្វាំង គូរី ហ្វ្រេនច រ៉ុស អ៊ីនដូនេស៊ី ម៉ាឡេស៊ី វៀតណាម ចិន និងភាសាផ្សេងទៀត។ Palantir Technologies ទើបតែជួបប្រទះការធ្លាក់ចុះពីកម្រិតខ្ពស់បំផុតជាប្រវត្តិសាស្ត្រ ដែលគូសបញ្ជាក់ពីសារៈសំខាន់នៃការតាមដានកម្រិតតម្លៃសំខាន់ៗ។ .
គោលដៅតម្លៃ TJX ត្រូវបានដំឡើងបន្ទាប់ពីត្រីមាសខ្លាំង
(SeaPRwire) - The TJX Companies, Inc. (NYSE:TJX) ថ្មីៗនេះបានរាយការណ៍ពីប្រាក់ចំណូលដែលលើសពីការរំពឹងទុករបស់ទីផ្សារ ដែលជំរុញឱ្យអ្នកវិភាគមួយចំនួនបង្កើនគោលដៅតម្លៃរបស់ពួកគេសម្រាប់ភាគហ៊ុនរបស់ក្រុមហ៊ុន។ ការអភិវឌ្ឍន៍នេះកើតឡើងនៅពេលដែល TJX បន្តបង្ហាញភាពធន់របស់ខ្លួននៅក្នុងវិស័យលក់រាយដែលមានការប្រកួតប្រជែង ដោយទាញយកផលប្រយោជន៍ពីគំរូអាជីវកម្មតែមួយគត់ និងគំនិតផ្តួចផ្តើមកំណើនជាយុទ្ធសាស្ត្ររបស់ខ្លួន។ ក្នុងរយៈពេលត្រីមាសកន្លងមក TJX បានរាយការណ៍ពីតួលេខលក់ដ៏រឹងមាំ ដែលជំរុញជាចម្បងដោយចរាចរណ៍អ្នកទិញកើនឡើង និងយុទ្ធសាស្ត្រសារពើភ័ណ្ឌដែលទទួលបានជោគជ័យ។ សមត្ថភាពរបស់ក្រុមហ៊ុនក្នុងការផ្តល់ជូននូវទំនិញម៉ាកល្បីៗជាច្រើនប្រភេទក្នុងតម្លៃបញ្ចុះតម្លៃបានធ្វើឱ្យមានការចាប់អារម្មណ៍យ៉ាងខ្លាំងពីអតិថិជន ជាពិសេសនៅក្នុងបរិយាកាសសេដ្ឋកិច្ចដែលអ្នកទិញទំនិញកាន់តែមានភាពរសើបចំពោះតម្លៃ។ វិធីសាស្រ្តនេះមិនត្រឹមតែជួយបង្កើនប្រាក់ចំណូលកំពូលរបស់ក្រុមហ៊ុនប៉ុណ្ណោះទេ ថែមទាំងអនុញ្ញាតឱ្យខ្លួនដណ្តើមយកចំណែកទីផ្សារពីអ្នកលក់រាយបែបបុរាណដែលបានតស៊ូដើម្បីសម្របខ្លួនទៅនឹងចំណង់ចំណូលចិត្តរបស់អ្នកប្រើប្រាស់ដែលផ្លាស់ប្តូរ។ លើសពីនេះទៅទៀត កិច្ចខិតខំប្រឹងប្រែងពង្រីកអន្តរជាតិរបស់ TJX បានចាប់ផ្តើមផ្តល់ផ្លែផ្កា។ ក្រុមហ៊ុនបានពង្រីកខ្លួនដោយជោគជ័យនៅក្នុងទ្វីបអឺរ៉ុប និងអូស្ត្រាលី ដែលជាតំបន់ដែលមានឱកាសកំណើនគួរឱ្យកត់សម្គាល់ដោយសារតែទីផ្សារអ្នកប្រើប្រាស់ធំ និងចំណង់អាហារសម្រាប់ជម្រើសលក់រាយដែលផ្តោតលើតម្លៃ។ ការពង្រីកជាយុទ្ធសាស្ត្រនេះត្រូវបានគេរំពឹងថានឹងបន្តរួមចំណែកជាវិជ្ជមានដល់លំហូរប្រាក់ចំណូលរបស់ TJX ក្នុងឆ្នាំខាងមុខនេះ។ អ្នកវិភាគក៏បានកត់សម្គាល់ផងដែរអំពីការគ្រប់គ្រងដ៏ប៉ិនប្រសប់របស់ TJX លើបញ្ហាប្រឈមនៃខ្សែសង្វាក់ផ្គត់ផ្គង់ដែលបានធ្វើឱ្យឧស្សាហកម្មលក់រាយមានការលំបាកជាសកល។ តាមរយៈការទាញយកទំនាក់ទំនងយូរអង្វែងជាមួយអ្នកផ្គត់ផ្គង់ និងការប្រើប្រាស់យុទ្ធសាស្ត្រភស្តុភារទំនើបៗ TJX បានរក្សាបាននូវលំហូរសារពើភ័ណ្ឌថេរ ដោយធានាថាម៉ាស៊ីនរបស់ខ្លួននៅតែផ្ទុកទំនិញដែលចង់បាន។ ប្រសិទ្ធភាពប្រតិបត្តិការនេះគឺជាកត្តាសំខាន់នៅក្នុងសមត្ថភាពរបស់ក្រុមហ៊ុនក្នុងការផ្តល់នូវកំណើនប្រាក់ចំណូលជាប់លាប់។ បន្ថែមពីលើឧត្តមភាពប្រតិបត្តិការ TJX បានធ្វើការវិនិយោគយ៉ាងសំខាន់ក្នុងការបង្កើនវត្តមានឌីជីថលរបស់ខ្លួន។ ក្រុមហ៊ុនបានដាក់ចេញនូវគំនិតផ្តួចផ្តើមពាណិជ្ជកម្មអេឡិចត្រូនិកជាច្រើនដែលមានគោលបំណងបំពេញបន្ថែមប្រតិបត្តិការឥដ្ឋនិងបាយអរបស់ខ្លួន។ ខណៈពេលដែលការលក់ភាគច្រើនរបស់ TJX នៅតែកើតឡើងនៅក្នុងហាងលក់រាយ ក្រុមហ៊ុនទទួលស្គាល់ពីសារៈសំខាន់ដែលកំពុងកើនឡើងនៃវេទិកាអនឡាញដ៏រឹងមាំមួយ និងប្តេជ្ញាអភិវឌ្ឍឆានែលនេះបន្ថែមទៀត។ ដោយសារតែការអភិវឌ្ឍន៍វិជ្ជមានទាំងនេះ អ្នកវិភាគហិរញ្ញវត្ថុមួយចំនួនបានកែសម្រួលទស្សនវិស័យរបស់ពួកគេសម្រាប់ TJX ដោយលើកឡើងពីការអនុវត្តប្រាក់ចំណូលដ៏រឹងមាំរបស់ក្រុមហ៊ុន និងទីតាំងជាយុទ្ធសាស្ត្រជាហេតុផលសម្រាប់សុទិដ្ឋិនិយម។ ការយល់ស្របគឺថា TJX មានទីតាំងល្អក្នុងការបន្តដំណើរឡើងលើរបស់ខ្លួន ដែលធ្វើឱ្យវាក្លាយជាជម្រើសដ៏ទាក់ទាញសម្រាប់វិនិយោគិនដែលកំពុងស្វែងរកការប៉ះពាល់ទៅនឹងវិស័យលក់រាយ។ ទោះបីជាមានអារម្មណ៍វិជ្ជមានក៏ដោយ អ្នកវិភាគព្រមានថាហានិភ័យសក្តានុពលនៅតែមាន។ កត្តាសេដ្ឋកិច្ចម៉ាក្រូដូចជាអតិផរណា និងការផ្លាស់ប្តូរទម្លាប់នៃការចំណាយរបស់អ្នកប្រើប្រាស់អាចប៉ះពាល់ដល់ការអនុវត្តរបស់ TJX ។ លើសពីនេះ ទេសភាពប្រកួតប្រជែងនៃការលក់រាយកំពុងតែវិវឌ្ឍឥតឈប់ឈរ ជាមួយនឹងអ្នកចូលថ្មី និងអ្នកលេងដែលមានស្រាប់កំពុងប្រជែងគ្នាឥតឈប់ឈរដើម្បីដណ្តើមយកចំណែកទីផ្សារ។ ទោះយ៉ាងណាក៏ដោយ របាយការណ៍ប្រាក់ចំណូលថ្មីៗរបស់ TJX បានពង្រឹងជំហររបស់ខ្លួនជាអ្នកដឹកនាំនៅក្នុងផ្នែកលក់រាយក្រៅតម្លៃ ហើយគំនិតផ្តួចផ្តើមជាយុទ្ធសាស្ត្ររបស់ក្រុមហ៊ុនត្រូវបានគេរំពឹងថានឹងគាំទ្រដល់កំណើនប្រកបដោយនិរន្តរភាព។ វិនិយោគិន និងអ្នកវិភាគដូចគ្នានឹងតាមដានយ៉ាងដិតដល់នូវវឌ្ឍនភាពរបស់ TJX នៅពេលដែលខ្លួនធ្វើដំណើរឆ្លងកាត់បញ្ហាប្រឈម និងឱកាសនៃទីផ្សារលក់រាយ។ កំណត់ចំណាំ: អត្ថបទនេះត្រូវបានផ្តល់ជូនដោយអ្នកផ្គត់ផ្គង់មាតិកាដែលទីបញ្ចូល។ SeaPRwire (https://www.seaprwire.com/) មិនមានការធានា ឬ បញ្ចេញកំណត់ណាមួយ។ ប្រភេទ: ព័ត៌មានប្រចាំថ្ងៃ, ព័ត៌មានសំខាន់ SeaPRwire ផ្តល់សេវាកម្មផ្សាយពាណិជ្ជកម្មសារព័ត៌មានសកលសម្រាប់ក្រុមហ៊ុន និងស្ថាប័ន ដែលមានការចូលដំណើរការនៅលើបណ្ដាញមេឌៀជាង 6,500 បណ្ដាញ ប័ណ្ណប្រតិភូ 86,000 និងអ្នកសារព័ត៌មានជាង 350 លាន។ SeaPRwire គាំទ្រការផ្សាយពាណិជ្ជកម្មជាសារព័ត៌មានជាភាសាអង់គ្លេស ជប៉ុន ហ្រ្វាំង គូរី ហ្វ្រេនច រ៉ុស អ៊ីនដូនេស៊ី ម៉ាឡេស៊ី វៀតណាម ចិន និងភាសាផ្សេងទៀត។ អត្ថបទដើមពិភាក្សាអំពីការអនុវត្តហិរញ្ញវត្ថុរបស់ TJX និងប្រតិកម្មរបស់អ្នកវិភាគ។ . ```
Viking Therapeutics ភាគហ៊ុនធ្លាក់ចុះដោយសារលទ្ធផលសិក្សា
(SeaPRwire) - ថ្មីៗនេះ Viking Therapeutics បានជួបប្រទះការធ្លាក់ចុះយ៉ាងខ្លាំងនៃតម្លៃភាគហ៊ុនរបស់ខ្លួន បន្ទាប់ពីការចេញផ្សាយលទ្ធផលនៃការសិក្សាគ្លីនិកលើឱសថសម្រកទម្ងន់ប្រភេទលេបរបស់ខ្លួន។ ការសិក្សានេះមានគោលបំណងវាយតម្លៃប្រសិទ្ធភាព និងសុវត្ថិភាពនៃការព្យាបាល ប៉ុន្តែនវិនិយោគិនបានប្រតិកម្មអវិជ្ជមានចំពោះលទ្ធផល ដែលនាំឱ្យតម្លៃទីផ្សាររបស់ក្រុមហ៊ុនធ្លាក់ចុះយ៉ាងខ្លាំង។ ការសាកល្បងព្យាបាល ដែលជាដំណាក់កាលដ៏សំខាន់ក្នុងដំណើរការអភិវឌ្ឍន៍ឱសថ បានបង្ហាញថាថ្នាំសម្រកទម្ងន់ប្រភេទលេបមិនបានសម្រេចតាមគោលដៅចម្បងដែលកំណត់ដោយ Viking Therapeutics នោះទេ។ លទ្ធផលបានបង្ហាញថា ខណៈពេលដែលឱសថនេះមានសុវត្ថិភាព ប្រសិទ្ធភាពរបស់វាក្នុងការសម្រកទម្ងន់មិនសំខាន់ដូចការរំពឹងទុកនោះទេ។ លទ្ធផលនេះបានបង្កឱ្យមានការព្រួយបារម្ភក្នុងចំណោមវិនិយោគិនអំពីការរំពឹងទុកនាពេលអនាគតនៃឱសថ និងបំពង់ស្រាវជ្រាវរបស់ក្រុមហ៊ុន។ Viking Therapeutics (NASDAQ:VKTX) ធ្លាប់បានដាក់ក្តីសង្ឃឹមខ្ពស់លើឱសថនេះថាជាការផ្លាស់ប្តូរដ៏មានសក្តានុពលនៅក្នុងទីផ្សារសម្រកទម្ងន់ ដែលជាទីផ្សារប្រកួតប្រជែងខ្ពស់ និងរកប្រាក់ចំណេញបានច្រើន។ កិច្ចខិតខំប្រឹងប្រែងស្រាវជ្រាវ និងអភិវឌ្ឍន៍របស់ក្រុមហ៊ុនត្រូវបានផ្តោតលើការបង្កើតផលិតផលដែលអាចផ្តល់ជម្រើសងាយស្រួល និងមានប្រសិទ្ធភាពជំនួសឱ្យការព្យាបាលដែលមានស្រាប់។ ទោះជាយ៉ាងណាក៏ដោយ លទ្ធផលនៃការសាកល្បងបានជំរុញឱ្យមានការវាយតម្លៃឡើងវិញនូវលទ្ធភាពពាណិជ្ជកម្មរបស់ឱសថ។ ឆ្លើយតបទៅនឹងលទ្ធផលនៃការសិក្សា Viking Therapeutics កំពុងពិចារណាលើការស្រាវជ្រាវបន្ថែម និងការកែប្រែទម្រង់ឱសថដើម្បីបង្កើនប្រសិទ្ធភាពរបស់វា។ ក្រុមហ៊ុននៅតែប្តេជ្ញាចិត្តក្នុងការជំរុញផលប័ត្របេក្ខជនព្យាបាលរបស់ខ្លួន ដែលរួមបញ្ចូលការព្យាបាលសម្រាប់ជំងឺមេតាបូលីស និងជំងឺក្រពេញ។ ទោះបីជាមានឧបសគ្គនេះក៏ដោយ Viking Therapeutics ជឿជាក់ថា នៅតែមានសក្តានុពលក្នុងការបង្កើនប្រសិទ្ធភាពឱសថ និងដោះស្រាយតម្រូវការវេជ្ជសាស្ត្រដែលមិនទាន់បានបំពេញនៅក្នុងផ្នែកសម្រកទម្ងន់។ ប្រតិកម្មរបស់ទីផ្សារចំពោះលទ្ធផលនៃការសិក្សាបានគូសបញ្ជាក់ពីបញ្ហាប្រឈមដែលក្រុមហ៊ុនបច្ចេកវិទ្យាជីវសាស្ត្រ (biotech) ប្រឈមមុខក្នុងការអភិវឌ្ឍន៍ឱសថ។ វិនិយោគិនតែងតែមានប្រតិកម្មរហ័សចំពោះលទ្ធផលនៃការសាកល្បងព្យាបាល ព្រោះទាំងនេះមានផលប៉ះពាល់ដោយផ្ទាល់ទៅលើការវាយតម្លៃរបស់ក្រុមហ៊ុន និងសក្តានុពលចំណូលនាពេលអនាគត។ វិស័យបច្ចេកវិទ្យាជីវសាស្ត្រត្រូវបានគេស្គាល់ថាមានភាពប្រែប្រួលខ្ពស់ ដោយតម្លៃភាគហ៊ុនតែងតែប្រែប្រួលញឹកញាប់ដោយផ្អែកលើលទ្ធផលនៃការសាកល្បង និងការអនុម័តបទប្បញ្ញត្តិ។ អ្នកវិភាគកំពុងតាមដានយ៉ាងដិតដល់នូវជំហានបន្ទាប់របស់ Viking Therapeutics និងរបៀបដែលក្រុមហ៊ុនគ្រោងនឹងដោះស្រាយបញ្ហាដែលបានគូសបញ្ជាក់ដោយការសាកល្បង។ គណៈគ្រប់គ្រងរបស់ក្រុមហ៊ុនបានធានាដល់ភាគីពាក់ព័ន្ធថា ពួកគេកំពុងស្វែងរកយ៉ាងសកម្មនូវវិធីដើម្បីបង្កើនប្រសិទ្ធភាពរបស់ឱសថ ហើយប្តេជ្ញាចិត្តក្នុងការទំនាក់ទំនងប្រកបដោយតម្លាភាពអំពីការអភិវឌ្ឍន៍នាពេលអនាគត។ នៅពេលដែលឧស្សាហកម្មបច្ចេកវិទ្យាជីវសាស្ត្របន្តច្នៃប្រឌិត និងជំរុញព្រំដែនវិទ្យាសាស្ត្រវេជ្ជសាស្ត្រ ក្រុមហ៊ុនដូចជា Viking Therapeutics ប្រឈមមុខនឹងទាំងឱកាស និងបញ្ហាប្រឈម។ តម្រូវការសម្រាប់ដំណោះស្រាយសម្រកទម្ងន់ប្រកបដោយប្រសិទ្ធភាពនៅតែខ្ពស់ ហើយមានសុទិដ្ឋិនិយមថា ជាមួយនឹងការស្រាវជ្រាវ និងការអភិវឌ្ឍន៍បន្ថែម ការព្យាបាលថ្មីៗអាចនឹងលេចចេញមកដើម្បីបំពេញចន្លោះប្រហោងនៅក្នុងទីផ្សារ។ កំណត់សម្គាល់៖ អត្ថបទនេះត្រូវបានផ្តល់ជូនដោយអ្នកផ្គត់ផ្គង់មាតិកាដែលទីបញ្ចូល។ SeaPRwire (https://www.seaprwire.com/) មិនមានការធានា ឬ បញ្ចេញកំណត់ណាមួយ។ ប្រភេទ: ព័ត៌មានប្រចាំថ្ងៃ, ព័ត៌មានសំខាន់ SeaPRwire ផ្តល់សេវាកម្មផ្សាយពាណិជ្ជកម្មសារព័ត៌មានសកលសម្រាប់ក្រុមហ៊ុន និងស្ថាប័ន ដែលមានការចូលដំណើរការនៅលើបណ្ដាញមេឌៀជាង 6,500 បណ្ដាញ ប័ណ្ណប្រតិភូ 86,000 និងអ្នកសារព័ត៌មានជាង 350 លាន។ SeaPRwire គាំទ្រការផ្សាយពាណិជ្ជកម្មជាសារព័ត៌មានជាភាសាអង់គ្លេស ជប៉ុន ហ្រ្វាំង គូរី ហ្វ្រេនច រ៉ុស អ៊ីនដូនេស៊ី ម៉ាឡេស៊ី វៀតណាម ចិន និងភាសាផ្សេងទៀត។ តម្លៃភាគហ៊ុនរបស់ Viking Therapeutics បានធ្លាក់ចុះយ៉ាងខ្លាំងបន្ទាប់ពីការចេញផ្សាយលទ្ធផលនៃការសិក្សា។ .
ភាគហ៊ុនថែទាំសុខភាពកំពូលសម្រាប់ទិន្នផលខ្ពស់
(SeaPRwire) - ការវិនិយោគលើភាគហ៊ុនសុខាភិបាលអាចជាយុទ្ធសាស្ត្រមួយដែលផ្ដល់ផលចំណេញខ្ពស់ ជាពិសេសសម្រាប់អ្នកដែលស្វែងរកឱកាសទទួលបានទិន្នផលខ្ពស់។ នៅពេលដែលចំនួនប្រជាជនពិភពលោកបន្តមានវ័យចំណាស់ និងតម្រូវការសេវាថែទាំសុខភាពកើនឡើង ក្រុមហ៊ុននានាក្នុងវិស័យនេះកំពុងស្ថិតក្នុងទីតាំងត្រៀមសម្រាប់ការរីកចម្រើន។ ក្រុមហ៊ុនពីរដែលលេចធ្លោក្នុងរឿងនេះគឺ AbbVie Inc. (NYSE:ABBV) និង Bristol-Myers Squibb (NYSE:BMY)។ ទាំងពីរនេះផ្ដល់ភាគលាភរឹងមាំ និងមានទីតាំងទីផ្សាររឹងមាំ។ AbbVie Inc. ដែលគេស្គាល់តាមរយៈថ្នាំដ៏ពេញនិយមរបស់ខ្លួនគឺ Humira បន្តពង្រីកវិសាលភាពផលប័ត្ររបស់ខ្លួនតាមរយៈការទិញយក និងការដាក់ចេញផលិតផលថ្មីៗ។ វិធីសាស្រ្តយុទ្ធសាស្ត្ររបស់ក្រុមហ៊ុនក្នុងការរីកចម្រើនបានអនុញ្ញាតឱ្យខ្លួនរក្សាបាននូវអត្ថប្រយោជន៍ប្រកួតប្រជែងនៅក្នុងឧស្សាហកម្មឱសថ។ ជាមួយនឹងទិន្នផលភាគលាភដ៏ស្ថិរភាពរបស់ខ្លួន AbbVie នៅតែជាជម្រើសដ៏ទាក់ទាញសម្រាប់វិនិយោគិនដែលផ្តោតលើចំណូល។ ស្រដៀងគ្នានេះដែរ Bristol-Myers Squibb បានដាក់ខ្លួនជាអ្នកដឹកនាំក្នុងការអភិវឌ្ឍការព្យាបាលប្រកបដោយនវានុវត្តន៍។ ការទិញយក Celgene ថ្មីៗនេះបានពង្រីកខ្សែផលិតផលរបស់ខ្លួន និងបង្កើនសមត្ថភាពស្រាវជ្រាវ និងអភិវឌ្ឍន៍របស់ខ្លួន។ ដំណើរការហិរញ្ញវត្ថុដ៏រឹងមាំរបស់ក្រុមហ៊ុន និងការប្តេជ្ញាចិត្តក្នុងការផ្តល់តម្លៃត្រឡប់ទៅអ្នកកាន់ភាគហ៊ុនវិញ ធ្វើឱ្យវាជាជម្រើសដ៏រឹងមាំសម្រាប់អ្នកដែលចង់វិនិយោគក្នុងវិស័យសុខាភិបាល។ ទាំង AbbVie និង Bristol-Myers Squibb មិនត្រឹមតែផ្តល់ឱ្យវិនិយោគិននូវសក្តានុពលសម្រាប់ការកើនឡើងដើមទុនប៉ុណ្ណោះទេ ប៉ុន្តែថែមទាំងផ្តល់ទិន្នផលភាគលាភដ៏ទាក់ទាញផងដែរ ដែលធ្វើឱ្យពួកវាស័ក្តិសមសម្រាប់ផលប័ត្ររយៈពេលវែង។ នៅពេលដែលវិស័យសុខាភិបាលបន្តវិវឌ្ឍ ក្រុមហ៊ុនទាំងនេះមានទីតាំងល្អក្នុងការទាញយកប្រយោជន៍ពីតម្រូវការដែលកំពុងកើនឡើងសម្រាប់ការព្យាបាល និងថ្នាំពេទ្យប្រកបដោយនវានុវត្តន៍។ កំណត់សម្គាល់៖ អត្ថបទនេះត្រូវបានផ្តល់ជូនដោយអ្នកផ្គត់ផ្គង់មាតិកាដែលទីបញ្ចូល។ SeaPRwire (https://www.seaprwire.com/) មិនមានការធានា ឬ បញ្ចេញកំណត់ណាមួយ។ ប្រភេទ: ព័ត៌មានប្រចាំថ្ងៃ, ព័ត៌មានសំខាន់ SeaPRwire ផ្តល់សេវាកម្មផ្សាយពាណិជ្ជកម្មសារព័ត៌មានសកលសម្រាប់ក្រុមហ៊ុន និងស្ថាប័ន ដែលមានការចូលដំណើរការនៅលើបណ្ដាញមេឌៀជាង 6,500 បណ្ដាញ ប័ណ្ណប្រតិភូ 86,000 និងអ្នកសារព័ត៌មានជាង 350 លាន។ SeaPRwire គាំទ្រការផ្សាយពាណិជ្ជកម្មជាសារព័ត៌មានជាភាសាអង់គ្លេស ជប៉ុន ហ្រ្វាំង គូរី ហ្វ្រេនច រ៉ុស អ៊ីនដូនេស៊ី ម៉ាឡេស៊ី វៀតណាម ចិន និងភាសាផ្សេងទៀត។ AbbVie Inc. ត្រូវបានគេស្គាល់ថាជាថ្នាំល្បីរបស់ខ្លួនគឺ Humira។ Bristol-Myers Squibb ថ្មីៗនេះបានទិញយក Celgene ដើម្បីបង្កើនខ្សែផលិតផលរបស់ខ្លួន។
កំពូលភាគហ៊ុនដែលមានចលនាខ្លាំងក្នុងវិស័យបច្ចេកវិទ្យា
(SeaPRwire) - ទីផ្សារភាគហ៊ុនបានឃើញចលនាគួរឱ្យកត់សម្គាល់នៅថ្ងៃនេះ ដោយមានក្រុមហ៊ុនបច្ចេកវិទ្យាធំៗជាច្រើននាំមុខ។ គួរកត់សម្គាល់ថា Intel (NASDAQ:INTC), Palo Alto Networks (NASDAQ:PANW) និង Nvidia (NASDAQ:NVDA) បានជួបប្រទះការប្រែប្រួលយ៉ាងខ្លាំង។ ក្រុមហ៊ុនទាំងនេះមានសារៈសំខាន់នៅក្នុងវិស័យបច្ចេកវិទ្យា ដោយមានឥទ្ធិពលជាបន្តបន្ទាប់ទៅលើនិន្នាការទីផ្សារ។ Intel ដែលល្បីល្បាញដោយសារមីក្រូប្រូសេសស័ររបស់ខ្លួន បានឃើញភាគហ៊ុនរបស់ខ្លួនប្រែប្រួលបន្ទាប់ពីការប្រកាសថ្មីៗអំពីវឌ្ឍនភាពរបស់ខ្លួននៅក្នុងបច្ចេកវិទ្យាឧបករណ៍អេឡិចត្រូនិក។ យុទ្ធសាស្ត្ររបស់ក្រុមហ៊ុនក្នុងការបង្កើនសមត្ថភាពផលិតកម្មបានទាក់ទាញចំណាប់អារម្មណ៍យ៉ាងខ្លាំងពីវិនិយោគិន ដោយបង្កជាសំណួរអំពីជំហរទីផ្សាររយៈពេលវែងរបស់ខ្លួន។ Palo Alto Networks ដែលជាក្រុមហ៊ុនឈានមុខគេផ្នែកដំណោះស្រាយសន្តិសុខតាមប្រព័ន្ធអ៊ីនធឺណិត បានរាយការណ៍ពីប្រាក់ចំណូលដែលលើសពីការរំពឹងទុករបស់ Wall Street។ ដំណើរការដ៏រឹងមាំរបស់ក្រុមហ៊ុនបញ្ជាក់ពីតម្រូវការកើនឡើងសម្រាប់សន្តិសុខតាមប្រព័ន្ធអ៊ីនធឺណិត ខណៈដែលការគំរាមកំហែងតាមប្រព័ន្ធឌីជីថលកំពុងកើនឡើង។ វិនិយោគិនមានសុទិដ្ឋិនិយមចំពោះសក្តានុពលរបស់ Palo Alto Networks សម្រាប់ការរីកចម្រើនជាបន្តបន្ទាប់ ដោយសារការយកចិត្តទុកដាក់ជាសកលលើហេដ្ឋារចនាសម្ព័ន្ធសន្តិសុខតាមប្រព័ន្ធអ៊ីនធឺណិត។ Nvidia ដែលល្បីល្បាញដោយសារអង្គភាពដំណើរការក្រាហ្វិក (GPUs) ក៏បានក្លាយជាប្រធានបទព័ត៌មានដ៏លេចធ្លោជាមួយនឹងភាគហ៊ុនរបស់ខ្លួនដែលបានកើនឡើងយ៉ាងខ្លាំង បន្ទាប់ពីការបង្ហាញបច្ចេកវិទ្យា AI ចុងក្រោយរបស់ខ្លួន។ ការច្នៃប្រឌិតរបស់ Nvidia នឹងធ្វើបដិវត្តន៍ឧស្សាហកម្មផ្សេងៗ ចាប់ពីការលេងហ្គេមរហូតដល់យានយន្តស្វ័យប្រវត្តិ ដោយបង្កើនទំនុកចិត្តវិនិយោគិនទៅលើការរំពឹងទុកនាពេលអនាគតរបស់ខ្លួន។ ការវិវឌ្ឍន៍ទាំងនេះបានគូសបញ្ជាក់ពីលក្ខណៈថាមវន្តនៃវិស័យបច្ចេកវិទ្យា ដែលវឌ្ឍនភាពរហ័ស និងការសម្រេចចិត្តជាយុទ្ធសាស្ត្រអាចជះឥទ្ធិពលយ៉ាងខ្លាំងដល់ដំណើរការភាគហ៊ុន។ ខណៈដែលក្រុមហ៊ុនទាំងនេះបន្តច្នៃប្រឌិត និងសម្របខ្លួនទៅនឹងតម្រូវការទីផ្សារ ពួកវានៅតែជាតួអង្គសំខាន់ដែលត្រូវតាមដាននៅក្នុងទេសភាពហិរញ្ញវត្ថុ។ កំណត់សម្គាល់៖ អត្ថបទនេះត្រូវបានផ្តល់ជូនដោយអ្នកផ្គត់ផ្គង់មាតិកាដែលទីបញ្ចូល។ SeaPRwire (https://www.seaprwire.com/) មិនមានការធានា ឬ បញ្ចេញកំណត់ណាមួយ។ ប្រភេទ: ព័ត៌មានប្រចាំថ្ងៃ, ព័ត៌មានសំខាន់ SeaPRwire ផ្តល់សេវាកម្មផ្សាយពាណិជ្ជកម្មសារព័ត៌មានសកលសម្រាប់ក្រុមហ៊ុន និងស្ថាប័ន ដែលមានការចូលដំណើរការនៅលើបណ្ដាញមេឌៀជាង 6,500 បណ្ដាញ ប័ណ្ណប្រតិភូ 86,000 និងអ្នកសារព័ត៌មានជាង 350 លាន។ SeaPRwire គាំទ្រការផ្សាយពាណិជ្ជកម្មជាសារព័ត៌មានជាភាសាអង់គ្លេស ជប៉ុន ហ្រ្វាំង គូរី ហ្វ្រេនច រ៉ុស អ៊ីនដូនេស៊ី ម៉ាឡេស៊ី វៀតណាម ចិន និងភាសាផ្សេងទៀត។ ចលនាភាគហ៊ុនរបស់ Intel ឆ្លុះបញ្ចាំងពីកិច្ចខិតខំប្រឹងប្រែងរបស់ខ្លួនក្នុងការបង្កើនផលិតកម្មឧបករណ៍អេឡិចត្រូនិក។ . Palo Alto Networks ធ្វើបានល្អជាងការរំពឹងទុកប្រាក់ចំណូល ដោយគូសបញ្ជាក់ពីតម្រូវការសន្តិសុខតាមប្រព័ន្ធអ៊ីនធឺណិត។ . បច្ចេកវិទ្យា AI ចុងក្រោយបំផុតរបស់ Nvidia ត្រូវបានកំណត់ឱ្យជះឥទ្ធិពលយ៉ាងខ្លាំងដល់ឧស្សាហកម្មផ្សេងៗ។ .
ហេតុអ្វីបានជាភាគហ៊ុន UPS គួរឱ្យចាប់អារម្មណ៍?
(SeaPRwire) - United Parcel Service (NYSE:UPS) គឺជាក្រុមហ៊ុនឈានមុខគេមួយនៅក្នុងឧស្សាហកម្មដឹកជញ្ជូន និងឡូជីស្ទិក ដែលល្បីល្បាញដោយសារបណ្តាញទូលំទូលាយ និងសេវាកម្មគួរឱ្យទុកចិត្ត។ នៅពេលដែលតម្រូវការសម្រាប់ពាណិជ្ជកម្មតាមប្រព័ន្ធអេឡិចត្រូនិច (e-commerce) បន្តកើនឡើង UPS ស្ថិតក្នុងទីតាំងពិសេសមួយដើម្បីទាញយកប្រយោជន៍ពីកំណើននេះ។ ការវិនិយោគជាយុទ្ធសាស្ត្ររបស់ក្រុមហ៊ុនលើបច្ចេកវិទ្យា និងហេដ្ឋារចនាសម្ព័ន្ធ ត្រូវបានរៀបចំឡើងដើម្បីបំពេញតម្រូវការដែលកើនឡើងសម្រាប់ការផ្តល់សេវាដឹកជញ្ជូនលឿន និងមានប្រសិទ្ធភាពជាងមុន។ ប្រតិបត្តិការហិរញ្ញវត្ថុរបស់ UPS មានភាពរឹងមាំ ជាមួយនឹងកំណើនចំណូលជាប់លាប់ និងប្រាក់ចំណេញខ្ពស់។ ក្រុមហ៊ុនបានទទួលជោគជ័យក្នុងការបង្កើនប្រសិទ្ធភាពប្រតិបត្តិការ កាត់បន្ថយការចំណាយ និងបង្កើនប្រសិទ្ធភាព។ កិច្ចខិតខំប្រឹងប្រែងទាំងនេះមិនត្រឹមតែបានធ្វើឱ្យប្រសើរឡើងនូវប្រាក់ចំណេញប៉ុណ្ណោះទេ ថែមទាំងបានកំណត់ទីតាំង UPS ជាអ្នកដឹកនាំក្នុងវិស័យឡូជីស្ទិកទៀតផង។ ក្នុងប៉ុន្មានឆ្នាំថ្មីៗនេះ UPS បានផ្តោតលើការពង្រីកសមត្ថភាពផ្នែកដឹកជញ្ជូនសុខាភិបាល ដោយទទួលស្គាល់ពីតម្រូវការដែលកំពុងកើនឡើងសម្រាប់សេវាដឹកជញ្ជូនឯកទេសក្នុងវិស័យនេះ។ ការទិញយក Marken ដែលជាក្រុមហ៊ុនឈានមុខគេលើពិភពលោកក្នុងដំណោះស្រាយខ្សែសង្វាក់ផ្គត់ផ្គង់គ្លីនិក បានបញ្ជាក់ពីការប្តេជ្ញាចិត្តរបស់ UPS ក្នុងការBពង្រឹងជំហររបស់ខ្លួននៅក្នុងទីផ្សារដែលមានផលចំណេញនេះ។ ការប្តេជ្ញាចិត្តរបស់ក្រុមហ៊ុនចំពោះនិរន្តរភាព គឺជាហេតុផលមួយទៀតដែលត្រូវយកចិត្តទុកដាក់លើភាគហ៊ុនរបស់ UPS។ ជាមួយនឹងតម្រូវការកើនឡើងរបស់អ្នកប្រើប្រាស់សម្រាប់ប្រតិបត្តិការដែលមិនប៉ះពាល់ដល់បរិស្ថាន UPS បានអនុវត្តគំនិតផ្តួចផ្តើមបៃតងជាច្រើន។ ទាំងនេះរួមមានការវិនិយោគលើយានយន្តប្រើប្រាស់ប្រេងឥន្ធនៈជំនួស និងការបង្កើនប្រសិទ្ធភាពផ្លូវដឹកជញ្ជូនដើម្បីកាត់បន្ថយការបំភាយឧស្ម័ន។ កិច្ចខិតខំប្រឹងប្រែងបែបនេះមិនត្រឹមតែស្របតាមគោលដៅនិរន្តរភាពសកលប៉ុណ្ណោះទេ ប៉ុន្តែក៏ស្របនឹងចំណាប់អារម្មណ៍របស់វិនិយោគិនដែលយកចិត្តទុកដាក់បរិស្ថានផងដែរ។ លើសពីនេះ គោលនយោបាយភាគលាភរបស់ UPS មានភាពទាក់ទាញសម្រាប់វិនិយោគិនដែលស្វែងរកប្រាក់ចំណូលទៀងទាត់។ ក្រុមហ៊ុនមានប្រវត្តិបង់ភាគលាភជាប់លាប់ ដែលឆ្លុះបញ្ចាំងពីលំហូរសាច់ប្រាក់ដ៏រឹងមាំ និងស្ថិរភាពហិរញ្ញវត្ថុរបស់ខ្លួន។ នេះធ្វើឱ្យ UPS ជាជម្រើសដ៏ទាក់ទាញសម្រាប់វិនិយោគិនដែលផ្តោតលើប្រាក់ចំណូលដែលកំពុងស្វែងរកទិន្នផលដែលអាចទុកចិត្តបាន។ នៅលើផ្នែកប្រកួតប្រជែង UPS ប្រឈមមុខនឹងបញ្ហាប្រឈមពីគូប្រជែងដូចជា FedEx និង Amazon។ ទោះជាយ៉ាងណាក៏ដោយ បណ្តាញដ៏ធំទូលាយ ភាពជឿនលឿនផ្នែកបច្ចេកវិទ្យា និងភាពជាដៃគូយុទ្ធសាស្ត្ររបស់ខ្លួន ផ្តល់នូវឧត្តមភាពក្នុងការប្រកួតប្រជែង។ សមត្ថភាពរបស់ UPS ក្នុងការសម្របខ្លួនទៅនឹងការផ្លាស់ប្តូរទីផ្សារ និងចំណង់ចំណូលចិត្តអ្នកប្រើប្រាស់ នឹងមានសារៈសំខាន់ក្នុងការរក្សាជំហរជាអ្នកដឹកនាំរបស់ខ្លួន។ សរុបមក ប្រតិបត្តិការហិរញ្ញវត្ថុដ៏រឹងមាំរបស់ UPS គំនិតផ្តួចផ្តើមយុទ្ធសាស្ត្រក្នុងផ្នែកដឹកជញ្ជូនសុខាភិបាល ការប្តេជ្ញាចិត្តចំពោះនិរន្តរភាព និងគោលនយោបាយភាគលាភដ៏ទាក់ទាញ ធ្វើឱ្យវាជាភាគហ៊ុនដែលគួរឱ្យចាប់អារម្មណ៍។ នៅពេលដែលឧស្សាហកម្មដឹកជញ្ជូនវិវឌ្ឍន៍ សមត្ថភាពរបស់ UPS ក្នុងការបង្កើតថ្មី និងសម្របខ្លួននឹងក្លាយជាគន្លឹះនៃភាពជោគជ័យរយៈពេលវែងរបស់ខ្លួន។ កំណត់ចំណាំ៖ អត្ថបទនេះត្រូវបានផ្តល់ជូនដោយអ្នកផ្គត់ផ្គង់មាតិកាដែលទីបញ្ចូល។ SeaPRwire (https://www.seaprwire.com/) មិនមានការធានា ឬ បញ្ចេញកំណត់ណាមួយ។ ប្រភេទ: ព័ត៌មានប្រចាំថ្ងៃ, ព័ត៌មានសំខាន់ SeaPRwire ផ្តល់សេវាកម្មផ្សាយពាណិជ្ជកម្មសារព័ត៌មានសកលសម្រាប់ក្រុមហ៊ុន និងស្ថាប័ន ដែលមានការចូលដំណើរការនៅលើបណ្ដាញមេឌៀជាង 6,500 បណ្ដាញ ប័ណ្ណប្រតិភូ 86,000 និងអ្នកសារព័ត៌មានជាង 350 លាន។ SeaPRwire គាំទ្រការផ្សាយពាណិជ្ជកម្មជាសារព័ត៌មានជាភាសាអង់គ្លេស ជប៉ុន ហ្រ្វាំង គូរី ហ្វ្រេនច រ៉ុស អ៊ីនដូនេស៊ី ម៉ាឡេស៊ី វៀតណាម ចិន និងភាសាផ្សេងទៀត។ UPS បានផ្តោតលើផ្នែកដឹកជញ្ជូនសុខាភិបាល ជាមួយនឹងការទិញយក Marken។ .
Intel ហក់ឡើង ដោយសារការវិនិយោគ ២ ពាន់លានដុល្លាររបស់ SoftBank
(SeaPRwire) - ក្នុងចលនាដ៏សំខាន់មួយ SoftBank បានវិនិយោគទឹកប្រាក់ 2 ពាន់លានដុល្លារក្នុងក្រុមហ៊ុន Intel ដែលជាចំណុចរបត់ដ៏សំខាន់សម្រាប់ក្រុមហ៊ុនផលិតបន្ទះឈីបដែលធ្លាប់ជួបការលំបាកមួយនេះ។ ការចាក់បញ្ចូលទុននេះ ត្រូវបានគេមើលឃើញថាជាកិច្ចខិតខំប្រឹងប្រែងជាយុទ្ធសាស្ត្រដើម្បីពង្រឹងជំហរទីផ្សាររបស់ Intel នៅចំពេលមានការប្រកួតប្រជែងយ៉ាងខ្លាំងក្លាក្នុងឧស្សាហកម្ម semiconductor។ ការវិនិយោគពី SoftBank នេះកើតឡើងចំពេលដែល Intel បានខិតខំប្រឹងប្រែងដើម្បីទទួលបានមូលដ្ឋានគ្រឹះរបស់ខ្លួនឡើងវិញក្នុងបច្ចេកវិទ្យាដែលរីកចម្រើនយ៉ាងឆាប់រហ័ស។ ក្រុមហ៊ុននេះបានប្រឈមមុខនឹងបញ្ហាជាច្រើនក្នុងរយៈពេលប៉ុន្មានឆ្នាំកន្លងមកនេះ រួមមានការរំខានខ្សែសង្វាក់ផ្គត់ផ្គង់ និងការប្រកួតប្រជែងយ៉ាងខ្លាំងក្លាពីក្រុមហ៊ុនយក្ស semiconductor ផ្សេងទៀតដូចជា AMD និង NVIDIA។ ភាគហ៊ុនរបស់ Intel (NASDAQ:INTC) បានកើនឡើងគួរឱ្យកត់សម្គាល់បន្ទាប់ពីការប្រកាសនេះ ដែលឆ្លុះបញ្ចាំងពីទំនុកចិត្តរបស់វិនិយោគិនទៅលើសក្តានុពលនៃការងើបឡើងវិញ។ ការគាំទ្រផ្នែកហិរញ្ញវត្ថុពី SoftBank នេះត្រូវបានគេរំពឹងថានឹងផ្តល់ឱ្យ Intel នូវធនធានចាំបាច់ដើម្បីច្នៃប្រឌិត និងពង្រីកការផ្តល់ជូនផលិតផលរបស់ខ្លួន។ អ្នកវិភាគបានណែនាំថាចលនានេះដោយ SoftBank គឺជាហានិភ័យដែលបានគណនា ដោយសារក្រុមហ៊ុននេះស្វែងរកការទាញយកផលចំណេញពីសក្តានុពលនៃការរីកចម្រើនរបស់ Intel។ ការវិនិយោគនេះស្របតាមយុទ្ធសាស្ត្ររបស់ SoftBank ក្នុងការគាំទ្រក្រុមហ៊ុនបច្ចេកវិទ្យាដែលត្រៀមខ្លួនសម្រាប់វឌ្ឍនភាពដ៏សំខាន់ក្នុងវិស័យរៀងៗខ្លួន។ ជាមួយនឹងទុនថ្មីនេះ Intel មានគម្រោងពន្លឿនកិច្ចខិតខំប្រឹងប្រែងស្រាវជ្រាវ និងអភិវឌ្ឍន៍របស់ខ្លួន ដោយផ្តោតលើបច្ចេកវិទ្យាទំនើបៗដូចជាបញ្ញាសិប្បនិម្មិត និងការរចនាបន្ទះឈីបកម្រិតខ្ពស់។ ក្រុមហ៊ុននេះមានគោលបំណងបង្កើនភាពប្រកួតប្រជែងរបស់ខ្លួន និងទាមទារទីតាំងជាអ្នកដឹកនាំក្នុងឧស្សាហកម្ម semiconductor ឡើងវិញ។ អ្នកជំនាញក្នុងឧស្សាហកម្មជឿជាក់ថាការវិនិយោគនេះអាចជាកត្តាជំរុញសម្រាប់ការសហការបន្ថែមទៀតរវាង Intel និងអ្នកច្នៃប្រឌិតបច្ចេកវិទ្យាផ្សេងទៀត។ តាមរយៈការទាញយកបណ្តាញដ៏ទូលំទូលាយ និងជំនាញរបស់ SoftBank, Intel អាចស្វែងរកភាពជាដៃគូ និងការបណ្តាក់ទុនថ្មីៗដែលអាចជំរុញកំណើននាពេលអនាគត។ ទោះជាយ៉ាងណា មាគ៌ាទៅមុខមិនមែនគ្មានឧបសគ្គទេ។ Intel ត្រូវតែឆ្លងកាត់ភាពស្មុគស្មាញនៃទីផ្សារ semiconductor សកលដែលមានលក្ខណៈដោយវឌ្ឍនភាពបច្ចេកវិទ្យាឆាប់រហ័ស និងតម្រូវការអ្នកប្រើប្រាស់ដែលផ្លាស់ប្តូរ។ លើសពីនេះ ក្រុមហ៊ុនត្រូវតែដោះស្រាយបញ្ហាផ្ទៃក្នុងដែលទាក់ទងនឹងប្រសិទ្ធភាពផលិតកម្ម និងការច្នៃប្រឌិតផលិតផល។ ទោះបីជាមានបញ្ហាប្រឈមទាំងនេះក៏ដោយ ការវិនិយោគថ្មីៗពី SoftBank បានចាក់បញ្ចូលនូវសុទិដ្ឋិនិយមជាថ្មីក្នុងចំណោមថ្នាក់ដឹកនាំ និងបុគ្គលិករបស់ Intel។ ក្រុមហ៊ុននេះឥឡូវមានទីតាំងល្អប្រសើរជាងមុនក្នុងការអនុវត្តចក្ខុវិស័យយុទ្ធសាស្ត្ររបស់ខ្លួន និងផ្តល់តម្លៃដល់ភាគទុនិករបស់ខ្លួន។ នៅពេលដែលឧស្សាហកម្ម semiconductor បន្តវិវត្ត សមត្ថភាពរបស់ Intel ក្នុងការសម្របខ្លួន និងច្នៃប្រឌិតនឹងមានសារៈសំខាន់ក្នុងការកំណត់ភាពជោគជ័យរយៈពេលវែងរបស់ខ្លួន។ ភាពជាដៃគូជាមួយ SoftBank តំណាងឱ្យជំហានដ៏សំខាន់មួយទៅមុខ ដោយផ្តល់ការគាំទ្រចាំបាច់ដើម្បីជួយ Intel ជំនះឧបសគ្គបច្ចុប្បន្នរបស់ខ្លួន និងចាប់យកឱកាសថ្មីៗក្នុងវិស័យបច្ចេកវិទ្យា។ កំណត់សម្គាល់៖ អត្ថបទនេះត្រូវបានផ្តល់ជូនដោយអ្នកផ្គត់ផ្គង់មាតិកាដែលទីបញ្ចូល។ SeaPRwire (https://www.seaprwire.com/) មិនមានការធានា ឬ បញ្ចេញកំណត់ណាមួយ។ ប្រភេទ: ព័ត៌មានប្រចាំថ្ងៃ, ព័ត៌មានសំខាន់ SeaPRwire ផ្តល់សេវាកម្មផ្សាយពាណិជ្ជកម្មសារព័ត៌មានសកលសម្រាប់ក្រុមហ៊ុន និងស្ថាប័ន ដែលមានការចូលដំណើរការនៅលើបណ្ដាញមេឌៀជាង 6,500 បណ្ដាញ ប័ណ្ណប្រតិភូ 86,000 និងអ្នកសារព័ត៌មានជាង 350 លាន។ SeaPRwire គាំទ្រការផ្សាយពាណិជ្ជកម្មជាសារព័ត៌មានជាភាសាអង់គ្លេស ជប៉ុន ហ្រ្វាំង គូរី ហ្វ្រេនច រ៉ុស អ៊ីនដូនេស៊ី ម៉ាឡេស៊ី វៀតណាម ចិន និងភាសាផ្សេងទៀត។ ការវិនិយោគរបស់ SoftBank ក្នុង Intel គឺជាកិច្ចខិតខំប្រឹងប្រែងជាយុទ្ធសាស្ត្រដើម្បីពង្រឹងជំហរទីផ្សាររបស់ក្រុមហ៊ុនផលិតបន្ទះឈីប។ .
Constellation Energy ភាគហ៊ុន គួរទិញទេ?
(SeaPRwire) - Constellation Energy (NASDAQ:CEG) ដែលជាអ្នកលេងដ៏លេចធ្លោមួយនៅក្នុងវិស័យថាមពល កំពុងទទួលបានការចាប់អារម្មណ៍ពីវិនិយោគិន ដោយសារតែដំណើរការជាប់លាប់ និងគំនិតផ្តួចផ្តើមកំណើនយុទ្ធសាស្ត្ររបស់ខ្លួន។ នៅពេលដែលក្រុមហ៊ុនបន្តពង្រីកវត្តមានរបស់ខ្លួននៅក្នុងថាមពលកកើតឡើងវិញ វិនិយោគិនជាច្រើនកំពុងពិចារណាថាតើពេលនេះជាពេលវេលាដ៏ត្រឹមត្រូវដើម្បីវិនិយោគលើភាគហ៊ុនរបស់ខ្លួនដែរឬទេ។ កត្តាចម្បងមួយដែលជំរុញចំណាប់អារម្មណ៍លើ Constellation Energy គឺការប្តេជ្ញាចិត្តរបស់ខ្លួនចំពោះនិរន្តរភាព និងដំណោះស្រាយថាមពលស្អាត។ ក្រុមហ៊ុនបានបណ្តាក់ទុនយ៉ាងសកម្មលើគម្រោងថាមពលកកើតឡើងវិញ រួមទាំងថាមពលពន្លឺព្រះអាទិត្យ និងថាមពលខ្យល់ ដើម្បីកាត់បន្ថយការបំភាយកាបូនរបស់ខ្លួន និងអនុលោមតាមគោលដៅបរិស្ថានសកល។ ការផ្តោតជាយុទ្ធសាស្ត្រនេះ មិនត្រឹមតែដាក់ Constellation Energy ជាអ្នកដឹកនាំក្នុងការផ្លាស់ប្តូរទៅអនាគតបៃតងប៉ុណ្ណោះទេ ប៉ុន្តែថែមទាំងបង្កើនភាពទាក់ទាញរបស់ខ្លួនចំពោះវិនិយោគិនដែលយកចិត្តទុកដាក់លើបរិស្ថានផងដែរ។ ហិរញ្ញវត្ថុ Constellation Energy បានបង្ហាញពីភាពធន់ និងកំណើន។ ក្រុមហ៊ុនបានរាយការណ៍ពីប្រាក់ចំណូលដ៏រឹងមាំនៅក្នុងត្រីមាសចុងក្រោយ ដោយសារភាពជោគជ័យរបស់ខ្លួនក្នុងការបង្កើនតម្រូវការសម្រាប់ថាមពពលស្អាត និងការគ្រប់គ្រងធនធានប្រកបដោយប្រសិទ្ធភាព។ សុខភាពហិរញ្ញវត្ថុរបស់ខ្លួនត្រូវបានពង្រឹងបន្ថែមដោយតារាងតុល្យការដ៏រឹងមាំ និងការអនុវត្តការគ្រប់គ្រងដោយប្រុងប្រយ័ត្ន។ កត្តាទាំងនេះរួមចំណែកដល់ទស្សនវិស័យវិជ្ជមានសម្រាប់ភាគហ៊ុនរបស់ក្រុមហ៊ុន ដែលធ្វើឱ្យវាក្លាយជាជម្រើសដ៏ទាក់ទាញសម្រាប់វិនិយោគិនរយៈពេលវែងដែលស្វែងរកស្ថិរភាព និងសក្តានុពលកំណើន។ លើសពីនេះ ភាពជាដៃគូយុទ្ធសាស្ត្រ និងការទិញយករបស់ Constellation Energy បានដើរតួនាទីយ៉ាងសំខាន់ក្នុងការបង្កើនជំហរទីផ្សាររបស់ខ្លួន។ តាមរយៈកិច្ចសហការជាមួយអ្នកលេងឧស្សាហកម្មសំខាន់ៗ និងការទិញយកទ្រព្យសកម្មជាយុទ្ធសាស្ត្រ ក្រុមហ៊ុនបានពង្រីកសមត្ថភាពប្រតិបត្តិការរបស់ខ្លួន និងបង្កើនចំណែកទីផ្សាររបស់ខ្លួន។ កិច្ចខិតខំប្រឹងប្រែងទាំងនេះ មិនត្រឹមតែជំរុញកំណើនចំណូលប៉ុណ្ណោះទេ ប៉ុន្តែថែមទាំងបង្កើតឱកាសសម្រាប់ការច្នៃប្រឌិត និងការរីកចម្រើនផ្នែកបច្ចេកវិទ្យាបាននៅក្នុងក្រុមហ៊ុនផងដែរ។ ទោះជាយ៉ាងណាក៏ដោយ ទោះបីជាមានទស្សនវិស័យល្អក៏ដោយ វិនិយោគិនដែលមានសក្តានុពលគួរតែពិចារណាពីហានិភ័យដែលមាននៅក្នុងវិស័យថាមពល។ ភាពប្រែប្រួលនៃទីផ្សារ ការផ្លាស់ប្តូរបទប្បញ្ញត្តិ និងការប្រកួតប្រជែងពីអ្នកផ្តល់ថាមពលកកើតឡើងវិញផ្សេងទៀត អាចប៉ះពាល់ដល់ដំណើរការរបស់ក្រុមហ៊ុន។ លើសពីនេះ ការប្រែប្រួលតម្លៃថាមពល និងភាពតានតឹងភូមិសាស្ត្រនយោបាយ អាចបង្កបញ្ហាដល់គន្លងកំណើនរបស់ខ្លួន។ សរុបមក ការប្តេជ្ញាចិត្តរបស់ Constellation Energy ចំពោះនិរន្តរភាព ដំណើរការហិរញ្ញវត្ថុដ៏រឹងមាំ និងគំនិតផ្តួចផ្តើមកំណើនយុទ្ធសាស្ត្រ ធ្វើឱ្យវាក្លាយជាឱកាសវិនិយោគដ៏ទាក់ទាញ។ ខណៈដែលវិស័យថាមពលបង្ហាញពីហានិភ័យជាក់លាក់ វិធីសាស្រ្តសកម្មរបស់ក្រុមហ៊ុនក្នុងការដោះស្រាយបញ្ហាប្រឈមទាំងនេះ និងការផ្តោតលើកំណើនរយៈពេលវែង ដាក់វានៅក្នុងទីតាំងអំណោយផលសម្រាប់អនាគត។ វិនិយោគិនដែលកំពុងស្វែងរកផលប័ត្រមានតុល្យភាព អាចរកឃើញថាភាគហ៊ុនរបស់ Constellation Energy ជាការបន្ថែមដ៏មានតម្លៃ ជាពិសេសសម្រាប់អ្នកដែលចាប់អារម្មណ៍ក្នុងការគាំទ្រការផ្លាស់ប្តូរទៅថាមពលកកើតឡើងវិញ។ កំណត់ចំណាំ៖ អត្ថបទនេះត្រូវបានផ្តល់ជូនដោយអ្នកផ្គត់ផ្គង់មាតិកាដែលទីបញ្ចូល។ SeaPRwire (https://www.seaprwire.com/) មិនមានការធានា ឬ បញ្ចេញកំណត់ណាមួយ។ ប្រភេទ: ព័ត៌មានប្រចាំថ្ងៃ, ព័ត៌មានសំខាន់ SeaPRwire ផ្តល់សេវាកម្មផ្សាយពាណិជ្ជកម្មសារព័ត៌មានសកលសម្រាប់ក្រុមហ៊ុន និងស្ថាប័ន ដែលមានការចូលដំណើរការនៅលើបណ្ដាញមេឌៀជាង 6,500 បណ្ដាញ ប័ណ្ណប្រតិភូ 86,000 និងអ្នកសារព័ត៌មានជាង 350 លាន។ SeaPRwire គាំទ្រការផ្សាយពាណិជ្ជកម្មជាសារព័ត៌មានជាភាសាអង់គ្លេស ជប៉ុន ហ្រ្វាំង គូរី ហ្វ្រេនច រ៉ុស អ៊ីនដូនេស៊ី ម៉ាឡេស៊ី វៀតណាម ចិន និងភាសាផ្សេងទៀត។ អត្ថបទកំណត់ចំណាំពិតប្រាកដពីអត្ថបទដើមជាមួយតំណភ្ជាប់ពិតប្រាកដ។ .
TANAKA PRECIOUS METAL GROUP and TANAKA MIRAI Lab. Successfully Carries Out Space Protein Crystallization Experiments
TOKYO, Aug 22, 2025 - (JCN Newswire via SeaPRwire.com) - TANAKA MIRAI Lab., part of TANAKA PRECIOUS METAL GROUP Co., Ltd. (head office: Chuo-ku, Tokyo; Group CEO: Koichiro Tanaka), has developed an experimental unit for space molecular crystallization using Au nanostructure formation technology (patent pending). On April 21, 2025 (local time), the experimental unit was installed in the SpaceX CRS-32, an unmanned commercial resupply spacecraft to the International Space Station (ISS) launched from the Kennedy Space Center in the U.S.Protein crystals formed within the experimental unit installed in the space station (magnified using a polarizing microscope)After installation in the ISS's Columbus science laboratory and one month of observation and experimentation, it safely returned to Earth, where it was confirmed that the experiments involving protein crystallization in space were successful.Significance of the ExperimentProtein crystallization experiments conducted in space are valuable for detailed structural analysis of protein molecules, as they can be carried out in a microgravity environment, eliminating the effects of gravity. Such experiments are expected to make significant contributions to understanding biological functions and advancing drug discovery. However, the success rate of producing crystals remains low, and the high costs along with the limited number of experiments that can be performed continue to pose challenges for space-based research. The experimental unit for space molecular crystallization, developed by TANAKA MIRAI Lab. and utilizing Au nanostructure formation technology, is expected to enable more cost-effective space experiments with superior outcomes. By leveraging protein crystallization technology based on the plasmon resonance (*1) of gold (Au), it can significantly improve the crystal generation rate. This advancement is anticipated to contribute to the elucidation of biological functions and to research in drug discovery.Superiority of “Experimental Unit for Space Molecular Crystallization Using Au Nanostructure Formation Technology”Protein molecules are easily absorbed onto the surface of Au nanoparticles, and plasmon resonance occurs between Au nanoparticles at wavelengths in the visible light range, promoting protein crystallization.TANAKA MIRAI Lab. has discovered that the condensation of light energy between Au nanoparticles further promotes the generation of protein crystal nuclei. In addition, in the microgravity environment of space, crystals of higher quality and larger size than those on the ground are expected to be generated because they are not affected by convection and sedimentation due to gravity.In combination with Au nanostructure formation technology, TANAKA MIRAI Lab. has developed a capillary (cylindrical glass device) (Figure 1) with high crystal generation capabilities (patent pending) for use in the counter-diffusion(*2) method.On the inner wall of the capillary with an inner diameter of 0.5 mm and a length of 5 cm, nano-level particles of Au (average diameter: 20 nm) are aligned at nano-level intervals (average distance between surfaces: 40 nm) that facilitate the generation of plasmon resonance near the surface of Au particles.In addition to conducting experiments in space, which is unaffected by gravity, the use of this unit is expected to dramatically improve the rate of obtaining protein crystals, which had been considered challenging. As a result, it is believed that this unit will contribute to the elucidation of biological functions and the development of drug discovery research.Figure 1: a) Photo of capillary b) Schematic diagram of capillary c) Electron microscope image of inner wallOverview of the ExperimentKirara, a space experiment service supplied by Japan Manned Space Systems Corporation (https://www.jamss.co.jp/en/space_utilization/kirara/), a space experiment consulting company, was used to install the experimental unit for space molecular crystallization using Au nanostructure formation technology in the SpaceX CRS-32 unmanned commercial resupply spacecraft.Specifically, capillaries were filled with protein solution and sealed in a tube (bag) which was stored within the Kirara device (a thermostatic chamber). This unit was then placed in the rocket and launched into space.Timeline of experiments involving protein crystallization in space* All times are U.S. local timesApril 7: Specimens sent from Japan to the U.S.April 13: Specimens arrive in Kennedy Space Center in Florida (U.S.)April 19: Specimens are loaded into Kirara device and placed in rocketApril 21: Kirara device is launched into space on a Space-X Falcon 9 rocket (CRS-32)April 22: Kirara device arrives at International Space Station (the ISS)April 23: Kirara device is installed in the ISS Columbus science laboratoryMay 21: Kirara device is removed from the ISS Columbus science laboratoryMay 25: CRS-32 with Kirara device returns to EarthResults of the ExperimentThe experimental unit for space molecular crystallization using Au nanostructure formation technology was used to successfully crystallize proteins in space (Figure 2).Figure 2: Top) Protein crystals formed in capillaries containing crystallization solution with NaCl concentration of 750 mMBottom) Magnified view of protein crystals taken using polarizing microscopeThe graph below (Figure 3) shows the final results of the protein crystallization experiment performed on the ISS(*3). The horizontal axis represents the concentration of the NaCl in the crystallization solution (mM). The vertical axis represents the average number of crystals that formed in the capillary (crystals per capillary).The blue bars (Au(-)) show the results for capillaries without Au nanostructures, while the red bars (Au(+)) show the results for capillaries with Au nanostructures.As the graph shows, the number of crystals that formed was higher for capillaries with Au nanostructures (the red bars on the graph).Experimental conditions● Capillary conditions: Capillaries with an inner diameter of 0.5 mm were used, and a structure of nano-level particles of Au with a diameter of 20 nm was formed on the inner walls of the capillaries (in the same way as for experiments performed on Earth in advance).● Solution conditions: Lysozyme refined for the space experiment was used as a solvent for protein (25 mg/L). For the crystallization solution, three NaCl concentrations were prepared: 650 mM, 700 mM, and 750 mM. These solutions included an acetic acid buffer (pH 4.5) with a concentration of 50 mM and PEG (4K) 20%.● Crystallization experiment: The counter-diffusion method was used, and the units were kept stationary at a temperature of 20°C in a weightless environment for 34 days, during which the crystallization process was observed.Comments from Researchers Responsible for the ExperimentTakayuki IshibashiChief Researcher, TANAKA MIRAI Lab.Ever since TANAKA MIRAI Lab. was first launched, we've envisioned precious metals as being used in extreme environments. Many projects never get beyond their planning phases, so I'm ecstatic that our first success was with an experiment in space, and that we've been able to exhibit the actual articles used in the experiment in our concept room here within the company. Seeing the proteins that crystallized in space here on Earth, with my own eyes, I felt again the potential for future crystal applications as we work toward the year 2085. We were able to achieve this success thanks to the combined efforts of many people, and I'd like to express my gratitude again to all those involved, both inside and outside the company.Masahiro ItoChief Researcher, TANAKA MIRAI Lab.This space project was a tremendously meaningful one for us, as it represented a great step forward. As a company that deals with precious metals, there have long been expectations for our participation in the space industry, but this was our first time really taking on a challenge in this sector. The project started out of a desire not just to think about things at the conceptual level but to test them out in space. I believe it reflects the spirit of TANAKA MIRAI Lab. — harnessing curiosity to drive our pursuit of creating rare and exceptional value for the future.Figure 4: Left) The experimental unit used in the ISS Right) Replica of the Kirara device(On exhibit in the DOCK2085 concept room at the head office)(*1) Plasmon resonance: A phenomenon in which light of a specific wavelength is absorbed on an Au surface that has been nanoparticulated. It is further enhanced when Au nanoparticles are close together at nano-level spacing.(*2) Counter-diffusion method: One of the protein crystallization methods, in which crystals are obtained by bidirectional diffusion of the protein solution inside the capillary and the crystallization solution outside. During this process, a concentration gradient is generated inside the capillary, which makes it possible to simultaneously search for a wide range of crystallization conditions. In addition, since the protein is not concentrated during crystallization, crystal growth proceeds gently.(*3) While more crystals were generated in the unit with the Au nanostructures, the experiments were performed under a limited number of experimental conditions, so this cannot be concluded to represent a significant difference. Furthermore, the overall number of crystals that were generated was low in comparison to prior experiments performed on Earth. This is believed to be due to a large number of days passing between when the capillaries were filled with solution and when the crystallization began.About TANAKA MIRAI Lab.TANAKA has been advancing a transformation of its overall business toward the year 2085, the 200th anniversary of its founding, with the aim of “creating a future that no one has ever seen before.” As part of this initiative, TANAKA launched TANAKA MIRAI Lab., an organization to lead the creation of new paradigms for a better future—from emergence to realization.TANAKA MIRAI Lab.’s mission is to envision an unseen future and realize various possibilities by conducting research derived from “kisho (precious and rare) value.”About TANAKASince its foundation in 1885, TANAKA has built a portfolio of products to support a diversified range of business uses focused on precious metals. TANAKA is a leader in Japan regarding the volume of precious metals it handles. Over many years, TANAKA has manufactured and sold precious metal products for industry and provided precious metals in such forms as jewelry and assets. As precious metals specialists, all Group companies in Japan and worldwide collaborate on manufacturing, sales, and technology development to offer a full range of products and services. With 5,591 employees, the group's consolidated net sales for the fiscal year ended December 2024 were 846.9 billion yen.TANAKA Industrial Precious Metal Materials Portalhttps://tanaka-preciousmetals.comPress inquiriesTANAKA PRECIOUS METAL GROUP Co., Ltd.https://tanaka-preciousmetals.com/en/inquiries-for-media/Press release: https://www.acnnewswire.com/docs/files/2025821.pdf Copyright 2025 JCN Newswire via SeaPRwire.com.
Lepu Biopharma (2157.HK) announces 2025 interim results
HONG KONG, Aug 21, 2025 - (ACN Newswire via SeaPRwire.com) - Focusing on the field of tumor treatment, innovative biopharmaceutical company Lepu Biopharma Co., Ltd. (Lepu Biopharma or the Company, stock code: 2157.HK) announced its interim results for the first half of 2025. During the reporting period, the Company's business showed strong growth momentum, achieving profitability for the first time. Core product sales and international licensing business progressed in tandem, with multiple ADC pipeline products entering key clinical stages and global commercialization efforts accelerating.Lepu Biopharma is an innovation-driven biopharmaceutical company focusing on oncology therapeutics, in particular, targeted therapy and oncology immunotherapy, with a strong China foundation and global vision. Lepu Biopharma is dedicated to developing innovative ADCs through our comprehensive and advanced ADC technology development platform and we aim to develop optimal and innovative drugs to better serve the unmet medical needs of cancer patients. The Company is committed to continuously developing a market-differentiating pipeline by fully integrating independent innovation capabilities and strategic collaborations. The Company has established and is progressively expanding our internal manufacturing capabilities, driven by the business needs stemming from the upcoming commercialization of our ADC candidates.Currently, Lepu Biopharma has strategically designed our pipeline with a range of oncology products. For clinical-stage candidates, the Company has one clinical/commercialization-stage drug candidate; nine clinical-stage drug candidates, including one co-developed through a joint venture; and three clinical-stage combination therapies of our candidates. One of our drug candidates has obtained marketing approval with respect to two of its targeted indications, with clinical trials for other indications ongoing. Among the nine clinical-stage drug candidates, seven are targeted therapeutics and two are immunotherapeutics, which are an oncolytic virus drug and T cell agonistic antibody.As of the end of the reporting period, Lepu Biopharma has achieved significant milestones in the monetisation of our R&D capabilities through commercialization and BD activities: PUYOUHENG (Pucotenlimab Injection) has completed the full commercialization process and is currently under a rapid sales growth, and four other products, CMG901, MRG007 and two pre-clinical TCE assets have also been licensed out through our BD activities. Notably, CMG901’s global rights have been licensed to AstraZeneca, and MRG007’s rights for regions outside Greater China have been licensed to ArriVent. Two pre-clinical TCE assets have entered into a collaboration with Excalipoint.Revenue scale achieved a 3.5-fold leapfrog growth, with comprehensive improvement in financial indicatorsIn the first half of 2025, the Company made significant progress in advancing its product pipeline and business operations, recording a total revenue of approximately RMB466 million, which was an increase of 350% of the same period in 2024 at RMB133 million. For licensing activities, the Company has recognized approximately RMB309 million in revenue primarily from the out-licensing of MRG007. The Company recorded a revenue of approximately RMB151 million for the sales of PUYOUHENG (Pucotenlimab Injection), marking a significant increase of 58.8% from the sales recorded in the same period in 2024. In addition, the Group recognized approximately RMB6.3 million in revenue for the provision of CDMO services.During the reporting period, the Company achieved profitability for the first time, with a profit of approximately RMB 29.3 million, marking a turnaround from a loss in the same period of 2024. Net cash generated from operating activities was approximately RMB 46.7 million, and cash and cash equivalents increased to approximately RMB 473 million, representing a positive net operating cash flow compared to the same period in 2024. Research and development expenses amounted to approximately RMB 202 million, representing a decrease of 6.6% compared to the same period in 2024. While ensuring the advancement of core pipelines, cost control measures have shown tangible results.The Company actively develops cooperative relationships with various business channel partners. As of June 30, 2025, the Company completed the tendering process on the procurement platform in 28 provinces of the PRC. We have covered approximately 118 cities in the PRC through various sales channels, and we will further expand our sales network.ADC pipeline enters the critical phase with multiple products, potential for combination therapy highlighted, and fruitful international licensing resultsIn the first half of 2025, the Company remained focused on the research and development of its drug candidates, while continuously assessing market demand and competitive landscape relating to the range of oncology therapeutics and the broad spectrum of indications covered by its drug candidates, in order to maximize the competitiveness of its products pipeline. In particular, MRG003 for NPC nears approval and other key drug candidates advance to pivotal clinical stage.MRG003（EGFR-ADCNPC: MRG003 is under NDA review for the treatment of R/M NPC and has also been granted priority review by the CDE of NMPA. The authority is currently proceeding with the clinical and pharmaceutical evaluation of MRG003. The encouraging data of the pivotal Phase IIb clinical study for the treatment of R/M NPC was read out as “late breaking abstract (LBA)” for oral presentation at the ASCO Congress 2025. The Company is also currently conducting the Phase III clinical trial of combination therapy with MRG003 and pucotenlimab on R/M NPC. The encouraging data in phase II clinical trial of combination therapy on R/M NPC will be presented at the ESMO Congress 2025.HNSCC: As of June 30, 2025, the Company is conducting a randomized, open-label, multicenter Phase III clinical study on HNSCC. In terms of combination therapy with MRG003 and pucotenlimab, we are currently conducting the Phase II clinical trial on HNSCC, and the encouraging data in phase II clinical trial will be presented at the ESMO Congress 2025. The European Medicines Agency (EMA) granted Clinical Trial Authorization (CTA) approvals for the Phase II clinical trial targeting LA-SCCHN in June 2025, and the Company will initiate the clinical trial in the second half of 2025.MRG004A (TF-ADC): The Company has completed the Phase I clinical study on solid tumors in China and the encouraging Phase Ib expansion data on PC will be presented at the ESMO Congress 2025. Protocol communication with CDE for the pivotal clinical trial of MRG004A has been completed, and we have entered the Phase III clinical trial stage in August 2025. In addition, MRG004A was granted BTD by the CDE in August 2025, which offers a brand-new treatment option to patients with pancreatic cancer.MRG006A (GPC3-ADC): MRG006A is a GPC3-targeted ADC with FIC potential globally. We received IND clearance from the FDA in January 2025. We are currently advancing Phase I clinical trial in China. In pre-clinical studies, MRG006A resulted in a robust and dose-dependent tumor growth inhibition on multiple CDX models and HCC PDX models. In the meantime, MRG006A also demonstrated good tolerability in the exploratory toxicology study.MRG007 (CDH17-ADC): We received the IND approval from the NMPA in June 2025 and are currently conducting a Phase Ia clinical trial for the treatment of unresectable locally advanced or metastatic solid tumors. MRG007 has shown robust antitumor activity in preclinical models of GI cancers and a favorable therapeutic index based on IND enabling studies. The pre-clinical data of MRG007 was presented at the AACR Annual Meeting in April 2025. In January 2025, the Company entered into an exclusive licensing agreement with ArriVent, pursuant to which the Company has granted ArriVent exclusive rights to develop, manufacture and commercialize MRG007 outside of Greater China. Under the terms of the agreement, the Company is eligible to receive up to US$1.2 billion in total in upfront payment and development, regulatory and sales milestones, together with tiered royalties on net sales. As of June 30, 2025, the upfront payment has been received.CG0070 (Oncolytic virus): CG0070 was granted BTD by the CDE in January 2025. CG0070 is currently in a MRCT Phase III clinical study conducted by the Company’s U.S. partner, CG Oncology. The latest encouraging data observed has been orally presented in the 120th American Urological Association Annual Meeting in April 2025. The Company has completed the Phase I clinical trial in China and are currently engaged in protocol communication with the CDE regarding the domestic bridging pivotal linical trial.Combination therapy layout: As of June 30, 2025, the Company has completed the Phase II trial of combination therapy with MRG002 and pucotenlimab in the treatment of HER2-expressing solid tumors, which has moved to first-line treatment, and protocol communication for phase III clinical trial has been completed. The Company has observed encouraging data on UC. In terms of combination therapy with MRG003 and pucotenlimab, the Company is currently conducting the Phase II clinical trial on HNSCC, which has moved to first-line treatment, and the encouraging data in phase II clinical trial will be presented at the ESMO Congress 2025. The European Medicines Agency (EMA) granted Clinical Trial Authorization (CTA) approvals for the Phase II clinical trial targeting LA-SCCHN in June 2025, and we will initiate the clinical trial in the second half of 2025, which has been moved up to first-line treatment for advanced disease.Preclinical: Laying the groundwork for innovative platforms and innovative targetsThe Company continuously strives to build up and develop novel technology platforms as innovative engines for the Company. The Company has developed multiple innovative linker-payload platforms for ADC drug candidates, including the Hi-TOPi ADC platform and other early-stage platforms. During the reporting period, our innovative ADC platforms have achieved significant progress. Based on these innovation platforms, the Company has generated two ADC candidates, which are MRG006A with global first-in-class potential and MRG007 with global best-in-class potential, all of which have shown encouraging pre-clinical data and received IND approvals in China. Pre-clinical data of MRG007 was presented at the AACR Annual Meeting in April 2025.On August 1, 2025, the Company entered into a licensing transaction for the license-out and/or transfer of certain intellectual property rights relating to two preclinical assets developed by the Company’s proprietary T cell engager-TOPAbody platform with Excalipoint through entering into the Intellectual Property Assignment and License Agreement.The Company shall receive (i) an upfront payment in cash of US$10 million in aggregate, development and commercial milestone payments in cash of up to US$847.5 million in aggregate and sales royalties, holding a 10% interest, marking international recognition of the platform's value.Future Outlook: Accelerating the Commercialization of Core Products and Advancing Global Strategic DevelopmentIn respect of drug R&D, the Company will further focus on advancing strategic research and development priorities in next generation ADC drugs and IO bi/tri specific antibodies, while accelerating the commercialization of late-stage products. For our registrational stage product MRG003, the relevant authority is currently proceeding with the clinical and pharmaceutical evaluation in an orderly manner. The Company will concentrate our resources and endeavour to expedite the approval process. Meanwhile, our other key drug candidates are entering pivotal clinical stages. Protocol communication for the pivotal clinical trial of MRG004A has been completed, and we have entered the Phase III clinical trial stage in August 2025. In addition, we are currently conducting protocol communication with the CDE regarding the domestic pivotal clinical trial of CG0070. The Company will also explore further potential clinical value of our other innovative drug candidates, such as MRG006A and MRG007. Concurrently, the potential efficacy of combination therapies within our pipeline is being continuously explored, with greater clinical benefits striving to be delivered to a broader patient population.In terms of domestic commercialization, the Company will take further actions to enhance the market accessibility of PUYOUHENG (Pucotenlimab Injection), accelerating market penetration at all levels to further increase market share and enhance the Company's brand image and market recognition. At the same time, the Company will commence the preparation process for the commercial launch of MRG003 and continue to expand our marketing and commercialization teams.On the international front, the Company will ramp up our efforts to expand into the global market. We will expand our international network and explore new business development cooperation opportunities. The Company will remain committed to seeking more strategic partners worldwide to develop our ADC products and other innovative candidates through partnerships, licensing agreements, or joint ventures. Copyright 2025 ACN Newswire via SeaPRwire.com.
NEC develops robot control technology using AI to achieve safe, efficient autonomous movement even at sites with many obstacles
TOKYO, August 21, 2025 - (JCN Newswire via SeaPRwire.com) — NEC Corporation (NEC; TSE: 6701) has developed technology that utilizes AI to enable safe, efficient autonomous control of robot movement even in complex environments with many obstacles. NEC’s in-house demonstrations of this technology have confirmed that a robot's travel time can be reduced by up to 50% when compared to conventional methods (*).This new technology utilizes NEC's proprietary AI, which has been trained with the knowledge of multiple AIs, to generate optimal travel paths in real time. NEC aims to commercialize this technology by the end of fiscal 2026.In recent years, automation through the introduction of robots has been progressing in large logistics warehouses and factories due to a decrease in labor forces and the need to improve productivity. However, in existing small- and medium-sized logistics warehouses, where it is difficult to prepare a dedicated environment for robots, and in retail stores, where aisles are narrow and display shelves and products are obstacles, it is difficult to secure paths for robots to move, which has hindered their introduction.Furthermore, in robot control technology, there has been a trade-off between the time required to predict a path and the quality of the estimated path, and it takes time to estimate optimal routes. Therefore, robot control technology has not been practical in complex environments with many obstacles.Features of the robot control technology developed by NEC to address these issues include the following.Proprietary AI that generates optimal routes in real timeTraditionally, autonomous robot navigation in environments with numerous obstacles has relied on a combination of AI technologies and methods that generate paths based on predefined rules and procedures. However, there have been challenges in achieving optimal path generation that balances safety and efficiency. Additionally, while combining multiple AI systems can generate more appropriate paths, increasing the number of AI systems tends to prolong processing time and make real-time control more difficult. NEC has developed a proprietary AI that can learn the paths generated by multiple AI systems and generate multiple paths at once. This enables the generation of safe and efficient optimal paths even in environments with irregularly placed obstacles, thereby realizing real-time robot control.50% reduction in robot travel timeIn simulations on a 50-meter-long test course with randomly placed obstacles, robots using this technology confirmed that the time required to run through the course could be reduced by up to 50% compared to conventional methods. This makes it possible to roughly double the efficiency of robot movement, while ensuring safety and contributing to further improvements in work efficiency on site.(*) Reinforcement Learning-based Dynamic Window Approach (RL-based DWA)About NECThe NEC Group leverages technology to create social value and promote a more sustainable world where everyone has the chance to reach their full potential. NEC Corporation was established in 1899. Today, the NEC Group’s approximately 110,000 employees utilize world-leading AI, security, and communications technologies to solve the most pressing needs of customers and society.For more information, please visit https://www.nec.com, and follow us on Instagram, Facebook, and LinkedIn.About NEC CorporationNEC Corporation has established itself as a leader in the integration of IT and network technologies while promoting the brand statement of “Orchestrating a brighter world.” NEC enables businesses and communities to adapt to rapid changes taking place in both society and the market as it provides for the social values of safety, security, fairness and efficiency to promote a more sustainable world where everyone has the chance to reach their full potential. For more information, visit NEC at https://www.nec.com. Copyright 2025 JCN Newswire via SeaPRwire.com.
Innovative Vaccine Engine Continues to Drive Growth: CanSinoBIO Enters a New Growth Cycle
HONG KONG, Aug 20, 2025 - (ACN Newswire via SeaPRwire.com) - In the first half of 2025, the structural transformation of the pharmaceutical industry continued to deepen. Driven by favorable policies, product upgrades, and technological innovation, the vaccine industry maintained a stable and positive growth momentum. As a leading enterprise in China’s innovative vaccine sector, CanSino Biologics Inc.(688185.SH, 6185.HK; CanSinoBIO) once again delivered a solid performance.According to its 2025 interim report, CanSinoBIO achieved revenue of RMB 382 million in the first half, up 26% from a year earlier, extending its growth streak. Although the company has yet to turn profitable, losses have narrowed significantly, with the reduction exceeding 94% compared to the same period last year. This reflects improved operational quality and lays a solid foundation for steady full-year growth. With core products selling strongly and multiple pipeline programs advancing, CanSinoBIO’s long-term growth story is steadily taking shape.Meningococcal Vaccine Portfolio Continues to Scale, Unlocking Growth DriversCanSinoBIO’s two currently marketed meningococcal conjugate vaccines—the quadrivalent meningococcal conjugate vaccine (MCV4, Menhycia) and the bivalent meningococcal conjugate vaccine (MCV2, Menphecia)—remain the company’s key revenue drivers. In particular, the sustained scaling-up of MCV4 demonstrates strong market competitiveness and is central to CanSinoBIO’s growth narrative.In 2024, Menhycia and Menphecia together generated nearly RMB 800 million in sales revenue, representing year-on-year growth of over 40%. In the first half of 2025, driven by deeper channel penetration and higher terminal market coverage, the sales of both vaccines continued to grow steadily. During the same period, the company’s meningococcal vaccine portfolio generated sales of over RMB 364 million, representing more than 38% year-on-year growth and providing a solid foundation for earnings.As the only MCV4 in China, Menhycia effectively covers four meningococcal serogroups, 'ACYW135', and leverages the high-safety CRM197 carrier protein technology. With outstanding clinical immunogenicity and safety, it has become the preferred choice for many parents seeking meningococcal vaccination for their children.Furthermore, Menhycia’s market potential is still being unlocked. The vaccine has been submitted to the National Medical Products Administration (NMPA) for an expanded age indication—from the current “children aged 3 months to 3 years (47 months)” to “children aged 3 months to 6 years (83 months).” If approved, this will directly broaden its coverage, strengthen penetration in the non-national immunization program market, and inject greater certainty into CanSinoBIO’s growth over the next two to three years, further consolidating the company’s leadership in the meningococcal vaccine field.iPneucia Officially Launched, a New Benchmark for Differentiated Pneumococcal VaccineIn June, CanSinoBIO’s self-developed product — the 13-valent pneumococcal conjugate vaccine (PCV13, iPneucia) — was officially approved for market launch, marking the company’s entry into the RMB 10 billion-plus pneumococcal vaccine market and the beginning of a new growth cycle.Pneumococcal diseases remain a serious global public health concern, with particularly high morbidity and mortality rates among children under five years old. Addressing the remaining immunization gaps in China, the launch of iPneucia fills the domestic technological void in high-end 13-valent pneumococcal conjugate vaccines, demonstrating CanSinoBIO’s leadership in differentiated innovation.Compared with existing competing products in the market, iPneucia achieves breakthroughs in three major dimensions. First, it offers more targeted protection, focusing on four high-risk serotypes—19F, 19A, 7F, and 3 - that together account for over 60% of pneumococcal disease cases among Chinese children. Clinical trial data show that its Geometric Mean Concentration (GMC) of antibodies is significantly higher than that of competing products. Second, in carrier protein technology, it adopts the globally pioneering CRM197+TT dual-carrier technology, overcoming the immune interference limitations of single-carrier vaccines. This both reduces the risk of immune suppression when co-administered with other vaccines and significantly enhances immunogenicity. Finally, in manufacturing safety, iPneucia uses an animal component - free fermentation process, reducing risks associated with animal-derived biological factors. It also employs no formaldehyde detoxification and adds no phenol during production, significantly improving vaccine safety.With these three advantages, iPneucia could potentially become another “ace” for CanSinoBIO in the infant bacterial vaccine market, following Menhycia. Notably, iPneucia shares a highly overlapping target population with Menhycia, creating strong channel synergies that will accelerate commercialization and enable the company to quickly capture market share in the RMB 10 billion-plus pneumococcal vaccine segment.Combination Vaccine Strategy Progresses SteadilyBeyond this, CanSinoBIO’s long-term potential lies in its continued build-out of a “Combination Vaccine” portfolio. Compared with traditional monovalent vaccines, multi-conjugate vaccine and polyvalent vaccine can prevent multiple diseases with a single injection, significantly improving vaccination efficiency and willingness - representing a key global direction in vaccine technology development.Following the quadrivalent vaccine Menhycia and multi-valent vaccine iPneucia, CanSinoBIO’s DTcP-Hib-MCV4 pentavalent vaccine—a representative combination vaccine—has attracted strong market attention. In February this year, it received clinical trial approval, marking a “zero-to-one” breakthrough for the company in the high-end combination vaccine sector.The DTcP-Hib-MCV4 pentavalent vaccine can simultaneously prevent pertussis, diphtheria, tetanus, Haemophilus influenzae type b (Hib) disease, and infection by the four meningococcal serogroups (ACYW135), achieving “protection against five diseases with a single shot”. This significantly reduces the number of injections and improves compliance among infants. More importantly, its core component Menhycia has already undergone commercial validation in China and enjoys a strong reputation, providing robust support for the combination vaccine’s development. This “point-to-surface” product upgrade logic enables CanSinoBIO to advance in the combination vaccine market with greater efficiency and confidence. With the government placing high importance on combination vaccine R&D and offering policy support, CanSinoBIO is well-positioned to capture this high-value market.R&D-Driven Growth with a Clear Product Pipeline and Strong ReservesWhile consolidating its existing market advantages, CanSinoBIO continues to strengthen its mid-to-long-term growth momentum through robust R&D capabilities and differentiated pipeline planning.Its DTcP for infants and young children has entered priority review and is expected to fill a domestic market gap. The Tdcp for people aged 6 years old and above has completed Phase III subject enrollment, enabling full life-cycle immunization coverage. The tetanus vaccine’s registration application has been accepted, and it is expected to offer superior safety and immunogenicity data compared with existing products. The Recombinant Poliomyelitis Vaccine, funded by Gates Foundation, has initiated clinical trials in Indonesia and has also received domestic clinical trial approval. Globally innovative Protein Based Pneumococcal Vaccine (PBPV) and inhaled tuberculosis vaccines have entered clinical research and proof-of-concept validation.The company has now built a rich pipeline covering multiple technology platforms and full life-cycle segments, including meningococcal vaccines, pneumococcal vaccines, diphtheria tetanus pertussis vaccine, polio vaccines, tuberculosis vaccines, and zoster vaccine. Several major products are entering critical stages of registration review or clinical trials. Meanwhile, CanSinoBIO’s continuous breakthroughs in key technology platforms support a strategic shift from reliance on single products to sustained pipeline output.Overall, in the first half of 2025, CanSinoBIO maintained the strong growth momentum seen since 2024, proving that its closed-loop capabilities from product R&D to commercialization have become increasingly mature. Against the backdrop of ongoing national policy support for innovative vaccines and domestic high-end vaccine substitution, CanSinoBIO — leveraging its solid R&D foundation, differentiated pipeline layout, and efficient commercialization execution—is accelerating the realization of its long-term growth potential and moving steadily toward becoming a global leader in innovative vaccines.CanSinoBIO, https://www.cansinotech.com [SSE:688185, HKG:6185, OTC:CASBF] Copyright 2025 ACN Newswire via SeaPRwire.com.
Graphene Manufacturing Group Ltd. Announces Bought Public Offering of Units for Gross Proceeds of C$5 Million
Brisbane, Queensland, Australia--(ACN Newswire via SeaPRwire.com - August 20, 2025) - Graphene Manufacturing Group Ltd. (TSXV: GMG) (OTCQX: GMGMF) ("GMG" or the "Company") is pleased to announce that it has entered into an agreement with Red Cloud Securities Inc. ("Red Cloud"), as sole underwriter and bookrunner, pursuant to which Red Cloud has agreed to purchase for resale 5,555,556 units of the Company (each, a "Unit") at a price of C$0.90 per Unit (the "Offering Price") on a "bought deal" basis in a public offering for gross proceeds of approximately C$5,000,000 (the "Underwritten Offering").Each Unit will consist of one common share of the Company (each, a "Unit Share") and one common share purchase warrant (each, a "Warrant"). Each Warrant shall entitle the holder to purchase one common share of the Company (each, a "Warrant Share") at a price of C$1.35 at any time on or before that date which is 36 months after the Closing Date (as herein defined).The Company has granted to the Underwriter an option (the "Over-Allotment Option", and together with the Underwritten Offering, the "Offering"), exercisable, in whole or in part, at any time for a period of up to 30 days after and including the Closing Date, to purchase for resale the number of additional Units equal to up to 15% of the number of Units sold pursuant to the Underwritten Offering at the Offering Price to cover over allotments, if any, and for market stabilization purposes.The net proceeds from the Offering will be used by the Company to fund ongoing operations including, but not limited to, commercial development, product development and working capital.In connection with the Offering, the Company intends to file a prospectus supplement (the "Supplement") to the Company's final short form base shelf prospectus dated March 7, 2025 (the "Shelf Prospectus"), with the securities regulatory authorities in each of the provinces and territories of Canada, except Quebec. The Units may also be sold in the United States on a private placement basis pursuant to one or more exemptions from the registration requirements of the United States Securities Act of 1933, as amended (the "U.S. Securities Act") and in such other jurisdictions outside of Canada and the United States, in each case in accordance with all applicable laws provided that no prospectus, registration statement or similar document is required to be filed in such jurisdiction, and provided the issuance of the Units (including the underlying securities) is permitted under laws applicable to the Company (including the Australian Corporations Act 2001 (Cth).Copies of the Shelf Prospectus and the Supplement to be filed in connection with the Offering can be found on SEDAR+ at www.sedarplus.ca. The Shelf Prospectus contains, and the Supplement will contain, important detailed information about the Company and the Offering. Prospective investors should read the Supplement, the Shelf Prospectus and the other documents the Company has filed on SEDAR+ at www.sedarplus.ca before making an investment decision.The Offering is expected to close on or about September 3rd, 2025 (the "Closing Date"), or on such date as agreed upon between the Company and Red Cloud. The closing of the Offering is subject to the Company receiving all necessary regulatory approvals, including the approval of the TSX Venture Exchange to list, on the Closing Date, the common shares of the Company issuable from the sale of Units as well as upon the exercise of the Warrants.This press release is not an offer to sell or the solicitation of an offer to buy the securities in the United States or in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to qualification or registration under the securities laws of such jurisdiction. The securities being offered have not been, nor will they be, registered under the U.S. Securities Act, and such securities may not be offered or sold within the United States or to, or for the account or benefit of, U.S. persons absent registration or an applicable exemption from U.S. registration requirements and applicable U.S. state securities laws.About GMGGMG is an Australian-based clean-technology company, which develops, makes and sells energy saving and energy storage solutions, enabled by graphene manufactured via in-house production process. GMG uses its own proprietary production process to decompose natural gas (i.e. methane) into its natural elements, carbon (as graphene), hydrogen and some residual hydrocarbon gases. This process produces high quality, low-cost, scalable, 'tuneable' and low/no contaminant graphene suitable for use in clean technology and other applications.The Company's present focus is to de-risk and develop commercial scale-up capabilities, and secure market applications. In the energy savings segment, GMG has initially focused on graphene enhanced heating, ventilation and air conditioning ("HVAC-R") coating (or energy saving coating), which is now being marketed into other applications, including electronic heat sinks, industrial process plants and data centres. Another product GMG has developed is the graphene lubricant additive focused on saving liquid fuels initially for diesel engines.In the energy storage segment, GMG and the University of Queensland are working collaboratively with financial support from the Australian Government to progress R&D and commercialization of graphene aluminium-ion batteries ("G+AI Batteries"). GMG has also developed a graphene additive slurry that is aimed to improve the performance of lithium ion batteries.GMG's 4 critical business objectives are:Produce Graphene and Improve/Scale Cell Production ProcessesBuild Revenue from Energy Savings ProductsDevelop Next-Generation BatteryDevelop Supply Chain, Partners & Project Execution CapabilityFor further information please contact:Craig Nicol, Chief Executive Officer & Managing Director of the Company at craig.nicol@graphenemg.com, +61 415 445 223Leo Karabelas at Focus Communications Investor Relations, leo@fcir.ca, +1 647 689 6041Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accept responsibility for the adequacy or accuracy of this news release.Cautionary Note Regarding Forward-Looking StatementsThis news release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws. Forward-looking statements relate to future events or future performance and reflect the expectations or beliefs of management of the Company regarding future events. Generally, forward-looking statements and information can be identified by the use of forward-looking terminology such as "intends", "expects" or "anticipates", or variations of such words and phrases or statements that certain actions, events or results "may", "could", "should", "would" or will "potentially" or "likely" occur. This information and these statements, referred to herein as "forward‐looking statements", are not historical facts, are made as of the date of this news release and include without limitation, statements regarding the expected size and terms of the Offering, the anticipated timing of closing the Offering, the ability of the Company to satisfy all conditions to closing the Offering, and the expected use of proceeds from the Offering.Such forward-looking statements are based on a number of assumptions of management, including, without limitation, expectations and assumptions concerning the business objectives of the Company; the Company's ability to carry out current planned capital projects, research and development, manufacturing, production, sales and marketing programs for its graphene and graphene-enhanced products and solutions; that the Company will receive the necessary regulatory approvals for the Offering; use the proceeds from the Offering as anticipated; the Company's performance and general business and economic conditions.Additionally, forward-looking information involves a variety of known and unknown risks, uncertainties and other factors which may cause the actual plans, intentions, activities, results, performance or achievements of GMG to be materially different from any future plans, intentions, activities, results, performance or achievements expressed or implied by such forward-looking statements. Such risks include, without limitation: the risk that the Company is not able to use the proceeds from the Offering as anticipated by management; the risk that the Company does not receive the requisite regulatory approvals for the Offering; overall economic conditions; technical de-risking and market acceptance for the Company's products and solutions; the introduction of competing technologies or products; stock market volatility; environmental and regulatory requirements; competitive pressures; change in market conditions and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied in these forward looking statements; the volatility of global capital markets; political instability; the failure of the Company to obtain regulatory approvals, attract and retain skilled personnel; unexpected development and production challenges; unanticipated costs and the risk factors set out under the heading "Risk Factors" in the Company's annual information form dated October 3, 2024 available for review on the Company's profile at www.sedarplus.ca.Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial outlook that are incorporated by reference herein, except in accordance with applicable securities laws.NOT FOR DISTRIBUTION TO THE U.S. NEWSWIRE OR FOR DISSEMINATION IN THE UNITED STATESTo view the source version of this press release, please visit https://www.newsfilecorp.com/release/263207 Copyright 2025 ACN Newswire via SeaPRwire.com.
Hengdeli Announces 2025 Interim Results
HONG KONG, Aug 20, 2025 - (ACN Newswire via SeaPRwire.com) - Hengdeli Holdings Limited (“Hengdeli” or the “Company” and, together with its subsidiaries, the “Group”; stock code: 3389) announced its interim results for the six months ended 30 June 2025 ("the period under review"). In the first half of 2025, the global environment remained complex and volatile, with uncertainties such as increasing trade barriers, intensifying trade frictions and continuing geopolitical conflicts weighing on the momentum of global economic growth. Under these pressures, China’s economic growth slowed down but maintained stable amidst multiple domestic and external challenges. Still, the country's economy remained resilient as it carried on with steady and sound development. In the face of a complex and volatile operating environment, the Group has adapted its business to market changes by adhering to the principle of “sound, steady and long-term operations” in order to preserve its market position and pursue new opportunities as well as make every effort to safeguard the interests of its shareholders.During the review period, the Group recorded revenue of RMB314,314,000 (six months ended 30 June 2024: RMB580,361,000), representing a year-on-year decrease of 45.8%; high-end consuming accessories business recorded revenue of RMB248,095,000 (six months ended 30 June 2024: RMB352,339,000), representing a year-on-year decrease of 29.6%; commodity trading revenue amounted to RMB66,219,000 (six months ended 30 June 2024: RMB228,022,000), representing a year-on-year decrease of 71.0%. During the period under review, the Group recorded a profit of RMB26,033,000 (six months ended 30 June 2024: profit of RMB499,000), representing a year-on-year increase of 5,117.0%. Profit attributable to equity shareholders amounted to RMB26,308,000 (six months ended 30 June 2024: loss of RMB2,504,000), representing a year-on-year increase of 1,150.6%. The profit was mainly attributable to foreign exchange gains incurred by the operating units as a result of exchange rate fluctuations.During the period under review, in view of uncertainties in the international market and the slowdown in domestic economic growth, the Group’s high-end consuming accessories business continued to face pressure. The Group has taken various measures to cope with the complicated operating environment, and continued to broaden its business models, acquire new customers and develop new products through innovative approaches. At the same time, the Group has enhanced its technological innovation capabilities, accelerated its mechanization, and standardized and strengthened its information and automation management. All these measures have yielded effective results and improved our ability to cope with risks. During the period under review, the sales performance and profit of the high-end consuming accessories business both recorded year-on-year decreases due to the impact of the operating environment.In terms of international trading, during the period under review, the Group continued to carry out the international commodity trading business in line with its established strategy. The business mainly covers the importation of iron ore, thermal coal and coking coal to Mainland China. Global demand for iron ore grew at a slower pace and prices weakened due to dampening economic prospects as a result of trade frictions. Impacted by fluctuating decline in sales prices of ore sand and weakened customer purchasing intentions, the sales and gross profits of the international commodity trading business decreased as compared to the same period last year but still maintained profitability. The Group planned to establish a bulk cargo transshipment logistics park in Mexico integrating customs clearance, import, transportation and warehousing, and has initiated collaborations with and provided services to multiple large-scale enterprises and listed companies in China. In the second half of the year, the Group will continue to keep abreast of market dynamics, promptly and prudently carry out international commodity trading activities and explore new profit models and future development directions, in order to lay a solid foundation for the Group’s sustainable development.In terms of international shipping, during the period under review, the Group’s international shipping business mainly focused on the global maritime transportation of dry bulk cargo, such as coal, iron ore, manganese ore, bauxite, grain and industrial salt. Our clientele includes internationally renowned mining enterprises and large central state-owned enterprises and listed companies in China. During the period under review, the global dry bulk shipping market was volatile, which affected the freight rates. The Group closely monitored the market conditions, continued to expand its business by developing new customers and signing long voyage transportation contracts with its customers to lock in long-term profits for the Company. In the first half of the year, affected by market fluctuations, both the revenue and profit of the Group’s shipping business recorded a decline.At present, the international political and economic environment is experiencing increased turbulence, with trade barriers and trade frictions worsening. Facing this severe external environment, the economy of Mainland China is also encountering difficulties and challenges, including insufficient demand, sluggish consumption awaiting stimulation, and ongoing structural adjustments. Nevertheless, the economy of Mainland China has a stable foundation, strong resilience and great potential, and the long-term positive development trajectory remains unchanged. With the implementation and refinement of various policies and measures by the Chinese government, we maintain full confidence in the long-term sustainable economic growth of Mainland China.In the second half of the year, the Group will adhere to the principle of “sound, steady, and long-term operations”, and will leverage the stable business environment in Mainland China that “pursues stability while seeking progress” to keep abreast of the market trend and further advance the progress of international trade business prudently and steadily. Additionally, the Group will continuously expand the shipping business, which is closely related to international trade, and strive to become an important participant in the international shipping supply chain, so as to provide support for the breakthroughs in corporate development.The Group will also adapt to changing market demands and continuously enhance its integrated service capabilities in commercial space for both Mainland China and international markets. We will adjust the manufacturing of high-end accessories for renowned watches while promoting a limited number of diversified business activities and expanding high-end consuming accessories manufacturing to other high-end lifestyle products, such as jewellery, eyeglasses, cosmetics, mobile phones and other 3C products. Additionally, we will expand our commercial space beautification services to living space beautification services, thus becoming an indispensable and independent segment in the ecological chain of high-end consuming accessories. Copyright 2025 ACN Newswire via SeaPRwire.com.
Focus Graphite Provides Update on Patent Application for Advanced Anode Materials Containing Silicon
Novelty and inventiveness confirmed as Focus Graphite moves closer to securing patent for next-generation lithium-ion battery anode materialsOttawa, Ontario--(ACN Newswire via SeaPRwire.com - August 20, 2025) - Focus Graphite Inc. (TSXV: FMS) (OTCQB: FCSMF) (FSE: FKC0) ("Focus" or the "Company") is pleased to provide an update on the status of its patent application entitled "Advanced Anode Materials Comprising Spheroidal Additive-Enhanced Graphite Particles and Process for Making Same" (Canadian patent application No. 3,209,696).The Company reports that no further prior art has been cited in the examination process. The remaining requests for clarification from the examiner are minor in nature, primarily relating to formality issues in the description and figures. Focus is pleased with this outcome and has retained MBM Intellectual Property Law ("MBM") of Ottawa, ON, to prepare and submit claim amendments and expects a positive resolution.In support of its application, Focus has also received the International Preliminary Report on Patentability ("IPRP") issued during the Patent Cooperation Treaty ("PCT"). The IPRP confirmed that the Company's amended claims are both novel and inventive, strengthening the intellectual property protection around Focus' proprietary anode material technology.Additionally, the Company submitted amended claims under the Patent Prosecution Highway ("PPH") for the Canadian case. These amendments, which reduced the number of claims to avoid excess fees, form the basis for the Company's ongoing patent strategy.Dean Hanisch, Chief Executive Officer of Focus Graphite, commented, "This positive progress in our patent application process represents another important milestone in advancing Focus Graphite's downstream strategy. The recognition that our claims are both novel and inventive underscore the uniqueness of our technology and its potential to contribute meaningfully to next-generation lithium-ion battery anode materials."The Company will provide further updates as the application advances.About MBM Intellectual Property LawMBM is an independent, Canadian-owned boutique law firm dedicated exclusively to intellectual property law headquartered in Ottawa. For over 30 years, MBM has provided strategic IP advice and protection for clients ranging from start-ups and universities to multinational corporations. With a diverse team of patent and trademark agents, lawyers, and scientists, MBM manages global patent, trademark, and design portfolios and is recognized for delivering practical, cost-effective solutions. Proudly independent, MBM focuses on building long-term client relationships and maximizing the value of innovation.About Focus Graphite Advanced Materials Inc. Focus Graphite Advanced Materials is redefining the future of critical minerals with two 100% owned world-class graphite projects and cutting-edge battery technology. Our flagship Lac Knife project stands as one of the most advanced high-purity graphite deposits in North America, with a fully completed feasibility study. Lac Knife is set to become a key supplier for the battery, defense, and advanced materials industries.Our Lac Tetepisca project further strengthens our portfolio, with the potential to be one of the largest and highest-purity and grade graphite deposits in North America. At Focus, we go beyond mining - we are pioneering environmentally sustainable processing solutions and innovative battery technologies, including our patent-pending silicon-enhanced spheroidized graphite, designed to enhance battery performance and efficiency.Our commitment to innovation ensures a chemical-free, eco-friendly supply chain from mine to market. Collaboration is at the core of our vision. We actively partner with industry leaders, research institutions, and government agencies to accelerate the commercialization of next-generation graphite materials. As a North American company, we are dedicated to securing a resilient, locally sourced supply of critical minerals - reducing dependence on foreign-controlled markets and driving the transition to a sustainable future.For more information on Focus Graphite Inc. please visit http://www.focusgraphite.comInvestors Contact: Dean HanischCEO, Focus Graphite Inc.dhanisch@focusgraphite.com+1 (613) 612-6060Jason LatkowcerVP Corporate Developmentjlatkowcer@focusgraphite.comCautionary Note Regarding Forward-Looking StatementsCertain statements contained in this press release constitute forward-looking information. These statements relate to future events or future performance. The use of any of the words "could," "intend," "expect," "believe," "will," "projected," "estimated," and similar expressions, as well as statements relating to matters that are not historical facts, are intended to identify forward-looking information and are based on the Company's current beliefs or assumptions as to the outcome and timing of such future events.In particular, this press release contains forward-looking information regarding, among other things, the anticipated outcome of Focus Graphite's patent application process; the Company's ability to address and resolve the examiner's remaining objections; the expectation of securing patent protection for spheroidal additive-enhanced graphite materials; the potential strategic, commercial, and technological benefits of securing such intellectual property; and the advancement of the Company's downstream strategy to supply advanced graphite materials for lithium-ion batteries in North America and globally.Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or achievements to differ materially from those expressed or implied by such statements. These risks and uncertainties include, but are not limited to, risks related to market conditions, regulatory approvals, changes in economic conditions, the ability to raise sufficient funds on acceptable terms or at all, operational risks associated with mineral exploration and development, and other risks detailed from time to time in the Company's public disclosure documents available under its profile on SEDAR+.The forward-looking information contained in this release is made as of the date hereof, and the Company is not obligated to update or revise any forward-looking information, whether as a result of new information, future events, or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties, and assumptions contained herein, investors should not place undue reliance on forward-looking information.Neither TSX Venture Exchange nor its Regulation Services accepts responsibility for the adequacy or accuracy of this release.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/263193 Copyright 2025 ACN Newswire via SeaPRwire.com.
Honda Establishes New Subsidiary in India for Retail Financing Services
TOKYO, Japan, August 20, 2025 - (JCN Newswire via SeaPRwire.com) – Honda Motor Co., Ltd. (Honda) today announced the recent establishment of a new company in India, Honda Finance India Private Ltd., (“Honda Finance India”) that will offer customers retail sales financing services including loans and lease sales options for Honda products in India.In India, where further growth of the motorcycle and automobile markets is expected, the number of customers using loans to purchase motorcycles and cars is also expected to increase. Until now, retail sales financing services in the Indian market have mainly been provided by local financial institutions. However, in light of market trends, Honda will further strengthen its business in India by offering its own sales financing services through a local subsidiary in India.Honda Finance India Private Ltd. will apply for a Non-Banking Financial Company (NBFC) license to conduct financial services business in India. After obtaining the license, the company will begin offering retail sales financing services to help customers finance their purchase of motorcycles, automobiles and services provided by Honda.Financial services business has been one of the main business areas of Honda, and the company has established local subsidiaries specializing in retail sales financing services in Japan and various countries in key regions such as North America, and Europe. With the establishment of the new company, India became the ninth country where Honda has a local subsidiary to offer financial services. Honda will work to establish long-term relationships with customers by offering flexible financial services tailored to the specific needs of customers in each region. Moreover, in anticipation of the global expansion of software-defined vehicle (SDV) sales in the future, Honda is looking into opportunities to offer new financial services designed to increase customer satisfaction and the value of the customer experience using various data from Honda SDVs. With such new services, Honda will further strengthen its financial services business not only in India but across the globe. About the new companyName of the company:Honda Finance India Private Ltd.Established:August 1, 2025Location:Gurugram District, Haryana, IndiaCapital:280 million Indian rupee (INR)Capitalization ratio:100% Honda Motor Co., Ltd.Representative:Kei Yamada, President Copyright 2025 JCN Newswire via SeaPRwire.com.
Collaborate with BNI, JCB Launch the 1st JCB Corporate Card in Indonesia
TOKYO & JAKARTA, Aug 20, 2025 - (JCN Newswire via SeaPRwire.com) - PT Bank Negara Indonesia (Persero) Tbk. (BNI) and PT JCB International Indonesia, a subsidiary of JCB International Co. Ltd., (JCB) proudly announce the launch of the BNI JCB Corporate Card in Indonesia. This premium credit card is thoughtfully designed to meet the diverse needs of Japanese corporations operating in Indonesia, supporting both their business operations and collaborations with local partners.Unveiled during BNI wondrX 2025, the card features an exclusive design inspired by the Tokyo cityscape. The launch event was attended by prominent figures including Masaki Yokawa, President & CEO of JCB International Co. Ltd.; Corina Leyla Karnalies, Consumer Banking Director of BNI; Abu Santosa Sudrajat, Treasury & International Banking Director of BNI; Rian Eriana Kaslan, Network & Retail Funding Director of BNI; and other board members.Masaki Yokawa, President & CEO of JCB International Co. Ltd., said: “The launch of our first corporate card product in Indonesia represents a significant milestone for JCB, as we aim to support the diverse business needs of Japanese companies and their local partners in the market. It also underscores our commitment to serving as a bridge between Japanese and Indonesian businesses, fostering stronger partnerships and enabling mutual growth through our financial services”.Corina Leyla Karnalies, Consumer Banking Director of BNI, added: “In line with the spirit of Be With You Every Step of the Way, corporate cardholders can enjoy various rewards that support their active and productive business activities, including complimentary access to executive lounge at five airports in Indonesia, green fee cashback at selected golf clubs, as well as special dining benefits at selected Japanese restaurants. Additional services include flexible credit limit adjustments, transaction notifications, 24/7 customer service, dedicated corporate PIC support, and assistance with corporate business travel needs through BNI TeleTravel.”As part of JCB's commitment to delivering valuable experiences for cardholders, particularly within the premium segment, BNI JCB Corporate cardholders also gain access to international airport lounges in Japan and other countries and territories. Additionally, they may enjoy exclusive benefits such as the Japan Dining Festival program in Indonesia. Looking ahead, JCB plans to introduce further programs and services designed to support the business growth of corporate cardholders.About BNI JCB Corporate CardThe card features a design inspired by the city of Tokyo, with a rising sun in the background symbolizing optimism and hope, reflecting a positive outlook for the future and a spirit of continuous growth.Companies can apply through the nearest BNI branch office, via the application link below, or a Relationship Manager via the Japan Desk.Application link: https://applycreditcard.bni.co.id/jcbcard?link_id=id_bni_jcbcard About JCBJCB is a major global payment brand and a leading credit card issuer and acquirer in Japan. JCB launched its card business in Japan in 1961 and began expanding worldwide in 1981. Its acceptance network includes about 56 million merchants around the world. JCB Cards are now issued mainly in Asian countries and territories, with more than 169 million cardmembers. As part of its international growth strategy, JCB has formed alliances with hundreds of leading banks and financial institutions globally to increase its merchant coverage and cardmember base. As a comprehensive payment solution provider, JCB commits to providing responsive and high-quality service and products to all customers worldwide. For more information, please visit: https://www.global.jcb/en/ContactAnna TakedaCorporate CommunicationsTel: +81-3-5778-8353Email: jcb-pr@info.jcb.co.jp Copyright 2025 JCN Newswire via SeaPRwire.com.
NEC collaborates with WFP to strengthen cooperative development in Africa
Tokyo, Japan, August 20, 2025 - (JCN Newswire via SeaPRwire.com) — NEC Corporation (NEC; TSE: 6701) today announced a Memorandum of Cooperation (MOC) with the United Nations World Food Programme (WFP) to strengthen collaborative development assistance in Africa, coinciding with the 9th Tokyo International Conference on African Development (TICAD 9). This will contribute to the aims of both parties to achieve the 2030 Agenda for Sustainable Development through innovative and efficient technology-enabled assistance, particularly in the areas of agriculture and global health/nutrition.WFP Executive Director, Cindy McCain (left) and NEC Corporate Senior Executive Vice President and CGAO, Shigehiro Tanaka (right)WFP, established in 1961, is a humanitarian aid agency of the United Nations whose mission is to eradicate world hunger by providing emergency food aid and development assistance in response to natural disasters and conflicts. Its activities are financed by contributions from national governments and donations from private organizations and individuals, and in 2024 it delivered food to approximately 124 million people.In recent years, the number of those in need of assistance has been increasing due to issues that include international conflicts, disasters, and pandemics, which pose serious challenges to achieving the United Nations Sustainable Development Goals (SDGs). WFP is working globally to create a world without hunger, and in order to achieve this goal with limited resources, it is essential to capitalize on technology that enhances the efficiency and effectiveness of assistance.WFP and NEC have launched initiatives for the monitoring of farmland in Ethiopia and Zambia, using the agricultural ICT platform "CropScope" (*1), and also collaborated to improve maternal and child nutrition in Ghana through the use of a digital health checkup mobile application (*2).Now, through the conclusion of this MOC, the organizations will contribute to building a more resilient and inclusive society by strengthening their collaboration mainly in the fields of agriculture and global health/nutrition, enhancing the functionality of CropScope and the digital health checkup mobile application, and utilizing various technologies to ensure sustainable development and to achieve the SDGs in Africa.Moreover, NEC will participate in the 9th Tokyo International Conference on African Development (TICAD 9) (*3) at Pacifico Yokohama in Yokohama, Japan, from August 20 (Wed.) to 22 (Fri.), 2025. During the event, NEC will hold seminars and exhibitions on agriculture and global health at the "TICAD Business Expo and Conference" and at the Japan Fair (*4)."We are pleased to strengthen our collaboration with WFP toward ensuring sustainable development in Africa. We are confident that, through this MOC, we can further create social value by co-creating with WFP and leveraging our expertise in technology."- Takayuki Morita, President and Chief Executive Officer, NEC(*1)Smart farming management | NEC(*2)Ajinomoto, Sysmex, and NEC improve maternal and child health and nutrition in Ghana: Press Releases | NEC(*3)The 9th Tokyo International Conference on African Development (TICAD 9)https://www.mofa.go.jp/region/africa/ticad/ticad9/index.html(*4)NEC to participate in "TICAD Business Expo and Conference" and thematic events for TICAD 9https://www.nec.com/en/press/202508/global_20250805_03.htmlAbout NEC CorporationNEC Corporation has established itself as a leader in the integration of IT and network technologies while promoting the brand statement of “Orchestrating a brighter world.” NEC enables businesses and communities to adapt to rapid changes taking place in both society and the market as it provides for the social values of safety, security, fairness and efficiency to promote a more sustainable world where everyone has the chance to reach their full potential. For more information, visit NEC at https://www.nec.com. Copyright 2025 JCN Newswire via SeaPRwire.com.
Kingsoft Announces 2025 Interim and Second Quarter Results
FINANCIAL HIGHLIGHTS RMB’000 (Unaudited)6 Months Ended June 303 Months Ended June 302025202420252024 Revenue4,645,407 4,610,641 2,307,412 2,473,766 - Office software and services2,657,122 2,413,079 1,355,653 1,187,730 - Online games and others1,988,285 2,197,562 951,759 1,286,036 Gross Profit3,772,214 3,782,688 1,853,628 2,042,035 Operating Profit984,111 1,395,615 382,658 794,037 Profit Attributable to Owners of Parent816,314 677,923 532,440 393,353 Basic Earnings Per Share (RMB)0.60 0.51 0.39 0.29 HONG KONG, Aug 20, 2025 - (ACN Newswire via SeaPRwire.com) - Kingsoft Corporation Limited (“Kingsoft” or the “Company”; HKEx stock code: 03888), a leading Chinese software and Internet service company, has announced its unaudited 2025 interim results and its second quarter results for the period ended 30 June 2025.For the first half of 2025, the revenue of Kingsoft increased by 1% year-on-year to RMB 4,645.4 million. Revenue from the office software and services represented 57% and online games and others represented 43% of total revenue. Gross profit reached RMB 3,772.2 million.For the second quarter of 2025, the Company’s revenue reached RMB 2,307.4 million. Revenue from office software and services and online games and others represented 59% and 41%, respectively, of total revenue for the second quarter of 2025. Gross profit for the second quarter of 2025 was RMB 1,853.6 million.Mr. Jun LEI, Chairman of the Company, commented: “In the second quarter, we advanced core businesses steadily in line with established strategy and firmly positioned for the future. Kingsoft Office focused on ‘AI, collaboration, and internationalization’, continued to strengthen the allocation of R&D resources in related fields, and developed solutions deeply aligned with user scenario needs to sustain competitiveness in the field of intelligent office. The online games business continued advancing content innovation and global expansion, achieving the development of flagship IPs and new game genres.”Mr. Tao ZOU, Chief Executive Officer of the Company, added: “The total revenue for the second quarter amounted to RMB 2,307.4 million, representing a year-on-year decrease of 7%, among which the revenue from the office software and services business was RMB 1,355.7 million, representing a year-on-year increase of 14%. Revenue from the online games and others business was RMB 951.8 million, representing a year-on-year decrease of 26%, primarily due to the high base in the same period last year.”BUSINESS REVIEWOffice Software and ServicesFor the first half of 2025, revenue from the office software and services business increased by 10% year-on-year to RMB 2,657.1 million. The increase was mainly attributable to the growth of WPS individual and WPS 365 businesses of Kingsoft Office. Revenue in the second quarter increased by14% year-on-year to RMB 1,355.7 million.In the second quarter, the office software and services business continued its healthy development. For WPS AI, Kingsoft Office released WPS AI 3.0 and launched the native Office intelligent agent ‘WPS Lingxi’ — the core capability module of WPS AI 3.0. WPS AI 3.0 drove deep integration between AI and office software through bidirectional transformation, achieving native embedding of AI capabilities and deep involvement in office workflows. WPS Lingxi integrated multiple AI functions, marking the transition from tool-based AI applications to collaborative intelligent agents. We also implemented intelligent upgrades to WPS 365 components, and launched messaging, meeting, and email assistants to boost office efficiency.For WPS individual business, Kingsoft Office expanded AI benefits and rolled out new AI products. In overseas markets, we initiated the development of the new WPS International Edition to gradually migrate domestic high-value features. For WPS 365 business, we continuously deepened penetration into industries and scenarios, actively promoted the implementation of AI projects, and engaged in co-creation with key clients to replicate and scale up typical solutions. For WPS software business, we actively participated in the bidding for domestic office software of central and local governments and enterprises. Our products maintained a leading share in both flow layout and fixed layout document software market.Online Games and othersFor the first half of 2025, revenue from online games and others business reached RMB 1,988.3 million, and revenue for the second quarter of 2025 was RMB 951.8 million. In the second quarter, the online games business continued to enrich the brand value of classic JX series and expand into new game genres.During the second quarter, JX3 Online, the flagship IP, maintained engaged player base through consistent content updates and technical optimization. The Fate of Sword: Zero was launched, building upon the core gameplay of the classic JX series IP while introducing innovative explorations. The anime shooter game Snowbreak: Containment Zone sustained its long-term operation, keeping stable user base. The self-developed sci-fi mech game Mecha BREAK commenced its global public beta in July. On its launch day, it topped Steam’s lists for both “Most Played” and “Trending Games,” and earned high scores from several international authoritative gaming outlets like IGN.Additionally, we actively strengthened our collaboration with high-quality overseas IPs, deepening the localized operational capabilities in domestic market. The social deduction game Goose Goose Duck obtained the license approval in June and was expected to launch in the second half of the year. The number of pre-registrations exceeded 5 million, demonstrating its popularity. Cats & Soup: Magic Recipe, the sequel to Cats & Soup, secured its license in May. For the latter half of the year, we will focus on refining the operations of our core titles and continuously optimizing the gaming experience based on players’ feedback.Mr. Jun LEI concluded, “In the coming quarters, Kingsoft Office will continue to increase its R&D investments in AI and collaboration, and promote the implementation of its products and services across a wider range of office scenarios in various industries. The online games business will remain focused on premium games, continue to cultivate its IP franchise, steadily advance its global expansion and achieve long-term operations. We believe that these efforts will strengthen the Group’s core competitiveness and lay a solid foundation to achieve long-term high-quality growth.”About Kingsoft Corporation LimitedKingsoft (3888.HK) is a leading Chinese software and internet service company listed on the Hong Kong Stock Exchange. It has three main subsidiaries: Kingsoft Office, Seasun Holdings and Kingsoft Shiyou. With the implementation of the “transformation toward mobile internet” strategy, Kingsoft has completed a comprehensive transformation in its overall business and management model. The Company has established a strategic layout with office software and interactive entertainment as its pillars, and cloud services and artificial intelligence as its new starting points. Kingsoft has more than 8,000 employees worldwide and holds a significant market share domestically. For more details, please refer to http://www.kingsoft.com.Kingsoft Investor Relations:Li YinanTel: +86 10 6292 7777Email: ir@kingsoft.comFor further queries, please contact Hill and Knowlton:Ovina ZhuTel: +852 2894 6315 Email: kingsofthk@hkstrategies.com Copyright 2025 ACN Newswire via SeaPRwire.com.